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             Pit1, a pituitary-specific transcription factor, regulates differentiation of cells of 
the PIT1 lineage in the anterior pituitary. PIT1 also regulates the synthesis of peptide 
hormones from these cell types, including growth hormone (GH). A founding member of 
the POU-homeodomain family of transcription factors, PIT1 is characterized by a serine-
threonine rich N-terminal transactivation domain and a C-terminal POU-domain. 
Alternative forms of PIT1, differing from each other in the N-terminal domain have been 
reported in several species, but the functional implication of having multiple isoforms is 
not known. Several Pit1 isoform mRNAs exist in chickens which have not been 
characterized. The main aim of this study was to determine which, if any, of the chicken 
 
 
PIT1 isoforms regulated the chicken Gh (cGh) promoter. PIT1β2, a novel isoform of 
chicken PIT1 was discovered, and known and novel isoforms (PIT1α, PIT1β1, PIT1β2 
and PIT1γ) were characterized. A luciferase reporter construct containing 1775bp of the 
cGh promoter driving expression of firefly luciferase was used to determine the ability of 
the isoforms to regulate the target gene promoter activity in chicken LMH cells. We 
showed that three of the isoforms, PIT1α, PIT1β1 and PIT1β2, expressed from 
recombinant plasmids, regulated the cGh promoter, while PIT1γ did not. All the isoforms 
localized to the nucleus in both non-pituitary and pituitary cells. Results from gel-shift 
assays show that PIT1γ did not bind the proximal PIT1-binding site of the cGh promoter 
as well as the other isoforms, suggesting a possible mechanism behind the inactivity. Our 
result did not suggest a negative regulatory role for this isoform. In contrast, we found a 
functional advantage for having multiple isoforms. PIT1β1, the isoform that activated the 
promoter most strongly, when co-transfected with other activating isoforms, such as 
PIT1α and PIT1β2, induced significantly higher level of activation than one isoform 
alone. Whether this increased activation required, or was facilitated by, 
heterodimerization of two isoforms is not known. Nevertheless, identification of isoforms 
with specific functions will facilitate identification of their respective interacting partners, 
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Chapter 1: Literature Review 
 
Regulation of genes and metabolic pathways affecting production traits in agricultural 
animals have expectedly been an active area of research over several decades. The 
anterior pituitary gland is called a master regulator of homeostasis, because it regulates 
numerous physiological processes, several of which affect agricultural animal 
performance. A thorough understanding of the action of the genes involved in growth, 
lactation and reproductive performances will be a valuable tool to employ in agricultural 
biology to extract maximal performance with minimal input. 
 
Growth hormone (GH), a peptide hormone released from the anterior pituitary gland, is 
essential for embryonic and posthatch growth in domestic chickens. In sex-linked dwarf 
chickens, a mutation of the GH receptor (GHR) results in a dwarf phenotype due to lack 
of GH signaling (Burnside et al., 1991; Huang et al., 1993). GH regulates metabolic 
processes such as lipolysis and muscle accretion. These two processes directly affect the 
quality of meat in broiler chickens. Posthatch administration of GH has little or no effect 
on growth rate in chickens. However, in ovo administration of GH at embryonic day 13 
(e13) results in improved growth after hatch (Blumenthal et al., 1954), suggesting the 
establishment of a growth threshold during embryonic development. Hence, 
understanding the mechanisms that establish growth parameters in the embryo is essential 




Comparison of the regulation of Gh gene expression across vertebrate species has 
identified several common themes as well as differences, most of which will be addressed 
in this review. In the general theme, GH is synthesized and secreted from the 
somatotrophs (GH producing cells) of the anterior pituitary gland. Signaling pathways 
and transcription factors orchestrate the development of the pituitary gland and functional 
maturation of the hormone producing cells. Somatotroph differentiation and Gh gene 
expression are influenced by hypothalamic factors such as growth hormone-releasing 
hormone (GHRH) and somatostatin (SST) (Romero and Phelps, 1997), as well as 
hormones from peripheral glands (adrenal glucocorticoids and thyroid hormones). 
Several transcription factors, such as PIT1, Sp-1, AP-2 (activator protein-2), 
glucocorticoid receptor (GR), thyroid hormone receptor (TR) and cAMP (3’-5’-cyclic 
adenosine monophosphate) response element binding protein (CREB) coordinate to 
maintain the tissue-specific expression of the Gh gene. Absence of one or more key 
elements of this machinery leads to absence or significant reduction of GH synthesis and 
secretion. This review will provide background information on the key points mentioned 
above.  
Development of the pituitary gland 
Formation of Rathke’s pouch (RP), a finger-like projection from the roof of the oral 
cavity toward the ventral diencephalon (VD) is the first step in pituitary development 
(Dasen & Rosenfeld, 2001). At about the same time, an outgrowth from the ventral 
diencephalon, called the infundibulum, starts developing toward RP. These two 
structures, after a series of developmental changes, give rise to the pituitary gland, with 
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RP forming the anterior lobe of the pituitary (adenohypophysis) and the infundibulum 
giving rise to the posterior lobe (neurohypophysis) (Wagner and Thomas, 2007). Physical 
contact between the RP and the infundibulum is essential for proper development of the 
pituitary gland, as the ventral diencephalon and infundibulum promotes growth of the 
anterior pituitary and final differentiation of the endocrine cell types (Ferrand 1972; 
Daikoku et al. 1982; Watanabe 1982(a,b); Fedtsova & Barabanov 1990).  
 
The anterior pituitary differentiates into five distinct cell types: corticotrophs, 
gonadotrophs, somatotrophs, lactotrophs and thyrotrophs (Dasen & Rosenfeld, 2001). A 
number of signaling molecules play essential roles in pituitary development (Fig. 1). 
Development of RP at the very initial stage requires bone morphogenetic protein (BMP) 
4 (Ericson et al. 1998, Treier et al. 1998; Takuma et al. 1998), but involvement of signals 
originating from the notochord has also been suggested. Sonic hedgehog (Shh), a secreted 
factor produced in the notochord is important for cell type specification and proliferation 
(Chiang et al. 1996; Fedtsova et al. 2003; Hammerschmidt et al., 1997; Treier et al., 
1998). Members of the fibroblast growth factor (FGF) family, especially FGF8 and 
FGF10 are expressed in the VD. FGF10 is essential for cell survival, while FGF8 
maintains proliferation and blocks BMP2 (discussed below).  
 
Two members of the BMP family have documented roles in pituitary development. As 
mentioned previously, BMP4 is required at the beginning of RP formation. The other 
member, BMP2, is solely expressed in the VD (Ericson et al. 1998, Treier et al. 1998). 







Fig. 1. Developmental stages, signaling molecules and selected transcription factors required for anterior 
pituitary development. Developmental stages denoted are for mouse. Top panel shows signaling molecules 
and morphological changes during pituitary development. Bottom panel shows transcription factors 





factors leading to specification of cell lineages, after which BMP2 is down-regulated to 
achieve terminal differentiation of the pituitary gland (Dasen and Rosenfeld, 2001). 
 
Notch signaling, required for early pituitary development, must be down-regulated during 
later phases to achieve terminal differentiation of cell lineages (Raetzman et al., 2006; 
Zhu et al., 2006). Constitutive expression of Notch leads to attenuated differentiation of 
all cell types of the anterior pituitary, as the factors Mash1 and Math3, both repressed by 
Notch, are critical for terminal differentiation (Raetzman et al., 2006; Zhu et al., 2006). 
The Wnt/β-catenin pathway is essential for terminal differentiation of cells of the PIT1 
lineage and overall pituitary gland growth. It is activated somewhat late during 
embryogenesis, and aberrant early activation causes premature down-regulation of 
transcription factor Hesx1, leading to failure of pituitary gland formation (Olson et al., 
2006). Among the Wnts, Wnt4 and Wnt5a have been shown to be directly involved in 
anterior pituitary formation (Cha et al., 2004; Treier et al., 1998).  
 
The list of transcription factors involved in pituitary development and differentiation is 
ever expanding but still far from complete. Some of them appear and act early, and may 
or may not need to be attenuated during further development. These early players usually 
show a more ubiquitous expression pattern throughout the developing embryo/fetus. 
Several members of the LIM Homeodomain proteins, for instance, Isl1, Lhx3 and Lhx4 
are expressed early in very specialized regions of the developing pituitary gland. Lhx3 is 
required for the formation of the definitive RP, but it also is needed later on for continued 
proliferation and prevention of apoptosis (Sheng et al., 1996). Isl1, another member of 
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the LIM group, is induced by BMP2 and opposed by FGF8, the classic target of the 
dorsal-ventral gradient necessary for pituitary differentiation (Ericson et al., 1998; 
Takuma et al., 1998). Hesx1, a paired-homeodomain transcription factor expressed in the 
RP and VD, is also essential for formation of the definitive pouch but later must be 
down-regulated (Dattani et al., 1998; Martinez-Barbera, 2000). Lhx3, Hesx1, and Pitx1 (a 
bicoid-related transcription factor) are induced initially to form the definitive pouch, 
following which Pitx2 is induced, Lhx3 is maintained, and Hesx1 is down-regulated to 
achieve terminal differentiation of the endocrine gland. Prop-1, another paired-like 
transcription factor, is the interaction partner of β-catenin in the complex that is 
responsible for the timely down-regulation of Hesx1 (Olsen et al. 2006; Sheng et al. 
1996; Sornson et al., 1996). 
 
After formation of the definitive pouch, a second set of transcription factors regulate 
further development, the most important being terminal differentiation of the hormone-
producing cells. In mammals, the corticotrophs are the first cell type to reach final 
differentiation, followed by the thyrotrophs, somatotrophs, lactotrophs and gonadotrophs, 
in their order of appearance (Japon et al., 1994; Simmons et al., 1990). Tbx19, a T-box 
transcription factor, is essential for terminal differentiation of corticotrophs and also for 
repression of alternate cell fates (Pulichino et al., 2003a, b). Three cell types, 
somatotrophs, lactotrophs, and thyrotrophs are characterized by the expression of one 
transcription factor, PIT1 (Cajiao et al., 2004; Dasen et al., 1999; Li et al., 1990), while 
gonadotrophs are characterized by the absence of it. The transcription factor unique to 
gonadotrophs is steroidogenic factor-1 (SF1) (Ingraham et al., 1994; Simmons et al., 
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1990). Thyrotrophs and gonadotrophs both express GATA2 (Charles et al., 2006), and it 
appears that the unique combination of PIT1 and GATA2 makes the cells thyrotrophs, 
and in the absence of PIT1, the cells adopt the fate of gonadotrophs. Conversely, 
gonadotrophs can be converted to thyrotrophs by the ectopic expression of PIT1 (Dasen 
et al., 1999; Gordon et al., 1997). These observations underline the importance and 
absolute requirements of these lineage-specifying transcription factors for proper 
pituitary development and function.  
 
The development of the pituitary in chicken shares many of the general developmental 
pathways and factors mentioned above, but differs from mammalian systems in some 
details. For instance, development of the infundibulum and from it, the posterior 
pituitary, is much less pronounced compared to mammals (Zhu et al., 2007). Expression 
of BMP4 differs between mouse and chicken: in chicken, it is expressed late, never in the 
RP, and never in levels comparable to that in mouse (Parkinson et al., 2010). The order of 
appearance of the different hormone-producing cell types also differs, with the 
corticotrophs and gonadotrophs being the first two types to appear almost simultaneously, 
followed by thyrotrophs, somatotrophs, and finally, the lactotrophs (Sasaki et al., 2003). 
Also, in mammals, somatotrophs and lactotrophs are thought to have originated from a 
common precursor, the somatomammotrophs (Asa et al., 1983), while in chickens, the 





Functions of growth hormone in vertebrates 
Growth hormone is involved in regulating a number of physiological processes in 
vertebrates, including long bone growth, lipid, carbohydrate and protein metabolism 
(Davidson et al., 1987), immune function (Koojman et al., 1996; Hooghe-Peters and 
Hooghe, 1998) and carcinogenesis. The ―Somatomedin hypothesis,‖ put forward in 1957 
(Salmon and Daughaday, 1957), postulated that the effects of GH on its target organs are 
not direct, and that they involve one or more intermediate factors (termed somatomedins; 
later identified to be insulin-like growth factors or IGFs) (Van Wyk et al., 1974). 
Decades of research in this area have proved this hypothesis to be partially true, and the 
hypothesis has been modified, with its present form stating that some actions of GH are 
direct while others are indirect (Le Roith et al., 2001). For instance, the GH effect on 
long bone growth appears to be direct. It is generally seen that the anabolic effects of GH, 
such as those involving bone, cartilage and skeletal muscle growth are direct and in some 
of these IGFs act in concert with GH towards the same end, but the action of GH itself is 
IGF-independent. However, in certain catabolic processes, such as lipid and carbohydrate 
metabolism (gluconeogenesis and adipogenesis), IGFs and GH have opposite effects, and 
IGFs are thought to counteract the effects of GH, which would otherwise be harmful 
(Kaplan and Cohen, 2007).  
 
In mammals, GH is the primary regulator of post-natal growth. Transgenic mice 
overexpressing GH grew almost twice as big as control littermates (Palmiter et al., 1983). 
Exogenous administration of GH in swine results in increased average daily gain (ADG), 
9 
 
muscle accretion and lipolysis (Campbell et al., 1989). GH also increases lactation in 
dairy cattle (Falaki et al., 1997). Apart from its obvious effects on bone growth, GH is 
necessary for normal female reproductive function, steroid metabolism, tooth 
development and modulation of gut function.  
 
In fish, apart from regulating growth throughout adult life, GH functions include 
regulation of metabolism by lipolysis and protein synthesis (Foster et al., 1991; 
Leatherland  and Farbridge, 1992;  O’Connor et al., 1996; Fauconneau et al., 2000), 
reproduction, osmoregulation (Bolton et al., 1987; Sakamoto et al., 1991), and immune 
development (reviewed in Yada et al., 2007). Osmoregulation by GH is brought about by 
morphological changes in gill chloride cells and by increasing the number of ion 
transporters in these cells, and this effect is believed to be IGF-dependent. Other 
vertebrate classes where GH exerts control over growth are reptiles (Denver and Licht, 
1990) and amphibians (Huang and Brown, 2000).  
 
Contrary to all other vertebrates, exogenous GH administration has no effect on growth 
and body weight in early post hatch broiler chickens (Burke et al. 1987; Cogburn et al., 
1989; Cravener et al., 1989; Scanes et al. 1990). However, pulsatile infusion of GH after 
the decrease of endogenous levels did have positive effects on bone growth and other 
metabolic parameters such as weight gain and feed efficiency (Vasilatos-Younken, 1988; 
Leung et al., 1986). Also, unlike in mammals, GH does not promote gluconeogenesis in 
avian species, and effects on lipid metabolism can be lipogenic or lipolytic depending on 
the age and mode of administration of GH.   
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While the pleiotropic nature of GH function is evident from the discussion above, 
regulation of body growth and development appears to be the major function of GH. GH 
synthesis and secretion is under the control of several hypothalamic and other endocrine 
factors, and the actions of GH, as mentioned previously, are mediated by IGFs produced 
either locally or by the liver (and carried by blood to the site of action). Hypothalamic 
regulators, GH, and IGFs constitute the somatotropic axis essential for post-natal growth. 
Evidence of the essentiality of the components and targets of the somatotropic axis comes 
mainly from mutant dwarf phenotypes, many of which will be discussed in this review. 
Classical pituitary ablation/replacement experiments have demonstrated that growth 
cessation resulting from hypophysectomy can be reversed by exogenous GH in chickens 
(Thommes et al., 1992; Scanes et al., 1986). In addition, both transgenic mice (Palmiter 
et al., 1983) and fish (Houdebine and Chourrout, 1991) overexpressing the Gh gene show 
marked increases in growth when compared to control animals. Also, it is well known 
that in humans, GH hyposecretion leads to dwarfism and hypersecretion to gigantism 
(before puberty) or acromegaly (in the case of adult onset). 
Gh gene structure 
The Gh gene has been evolutionarily conserved from lower vertebrates to birds and 
mammals; however, the structural arrangement of the primate Gh gene is markedly 
different from other vertebrate species. In most mammals and all birds and fish, Gh is a 
single gene, but in primates GH is encoded by a cluster of 5 genes. Genes that comprise 
this cluster are thought to have arisen as a result of gene duplication. The cluster includes 
the normal and variant forms of GH, GH-N and GH-V, respectively, along with genes for 
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placental lactogens (also called chorionic somatomammotropins, or CS). Of the genes 
present in this cluster, only GH-N is expressed in the pituitary somatotrophs, while GH-V 
and the CSs are expressed in the syncytiotrophoblasts of the placenta (Chen et al., 1989). 
 
The mammalian Gh gene is made up of 5 exons and 4 introns within an approximately 
3kb region (Tuggle and Trenkle, 1996). In fish, it can be either the same as mammals or 
contain 6 exons and 5 introns depending on the species. The Gh gene in chicken is 
located on chromosome 27, and, similar to mammals, comprises 5 exons and four introns, 
but the introns are larger than their mammalian counterparts, making the entire gene 
about 3.5kb. Alternative splicing of the hGh gene yields proteins of 22kDa and 20kDa, 
with the 22kDa form being much more abundant.  Among post-translational 
modifications, acylation, deamidation and glycosylation are known, and the first two 
display similar bioactivity, while the bioactivity of the glycosylated form is not known. 
Glycosylated forms have been reported for human, rat and chicken GH. 
Neuroendocrine regulation of GH synthesis and secretion 
GH is synthesized and secreted in a ultradian pulsatile manner (Winer et al., 1990) from 
somatotrophs, one of the five cell types that make up the anterior pituitary. Somatotroph 
differentiation requires blood-borne signals from outside the pituitary in all species 
(Nogami et al., 1995; Porter et al., 1995). Somatotrophs are the third pituitary cell type to 
arise in most species, and they are one of the most numerous cell types in adults. Growth 
hormone-releasing hormone (GHRH) and somatostatin (SST) are two hypothalamic 
factors that regulate GH production, with GHRH stimulating the synthesis and secretion 
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of GH and SST inhibiting it. Both SST and GHRH are essential for maintaining the 
pulsatality of GH secretion (Wehrenberg et al.,1982, Cella et al.,1990, Katakami et 
al.,1988, Frohman et al.,1989) even though the exact mechanism behind the pulsatality 
remains unknown. SST, the inhibitor of GH release, probably negatively regulates GHRH 
to bring about the pulsatility. 
 
GHRH belongs to the family of brain-gut peptides along with vasoactive intestinal 
peptide (VIP), glucagon, glucagon-like peptide I (GLPI), pituitary adenylate cyclase-
activating peptide (PACAP) etc. (Campbell et al., 1991). Functions of GHRH include 
stimulation of somatotroph differentiation, Gh gene transcription, biosynthesis, and 
secretion (Mayo et al., 1995). GHRH is a peptide hormone produced in the arcuate 
nucleus of the hypothalamus (Bloch et al.,1983). The actions of GHRH are mediated 
through its receptor, GHRH-R, a seven transmembrane G-protein coupled receptor linked 
to a stimulatory G-protein (Gs) (Gaylinn et al.,1993, Lin et al.,1992, Narayanon et al. 
1989, Spada et al.,1984), which activates adenylate cyclase (Spada et al.,1984), leading 
to an increase in intracellular cAMP and Ca
2+ 
levels (Holl et al.,1988). The activated G-
protein interacts with ion channels, leading to secretion of GH, whereas the elevated 
cAMP levels activate the protein kinase A (PKA) pathway that leads to increased 
transcription of the GH gene, possibly by phosphorylation of transcription factors and 
activators involved in the process (Holl et al., 1988). Evidence of the essentiality of 
GHRH signaling in GH regulation comes from the GHRH-R mutant little mouse (lit/lit), 
with a mutation of a conserved aspartic acid residue (Asp60Gly) in the N-terminal ligand 
binding domain. This mutation changes the protein structure, and the mutant receptor is 
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incapable of increasing cellular cAMP levels (Lin et al., 1993). Among vertebrates, the 
function of GHRH as a potent regulator of Gh has been established in mammals, birds, 
reptiles and one teleost, the goldfish.  
 
SST, the hypothalamic peptide hormone that inhibits GH synthesis (Brazeau et al.,1973), 
also acts through G-protein coupled receptors, of which there are six subtypes 
(Patel,1997). SST function has been conserved in vertebrates. In almost all species, SST 
does not decrease basal GH production at either RNA or protein levels; neither does it 
inhibit somatotroph proliferation, but rather it attenuates GHRH-induced GH expression 
(Barinaga et al.,1985, Billestrup et al.,1986, Fukata et al.,1985, Simard et al.,1986, 
Tanner et al.,1990). In chickens and teleosts, however, SST can affect both basal and 
GHRH-induced GH expression, while in reptiles and some amphibians, SST acts on 
thyrotropin releasing hormone (TRH)-stimulated GH expression (Hall and Chadwick, 
1984; Jeandel et al., 1998). SST possibly mediates its effect through decreasing 
intracellular cAMP levels and by affecting voltage-gated ion channels that lead to an 
increase in intracellular K
+
 levels and simultaneous decrease in Ca
2+
 levels, but the 
precise mechanism is still unclear (Epelbaum, 1992, Patel et al.,1995).  
 
Apart from these hypothalamic peptides, numerous growth hormone-releasing peptides, 
or GHRPs have been identified and characterized. GHRP-6 is the most potent peptide, 
being more potent than GHRH (Bowers, 1993; Bowers et al., 1990). The potency of it 
has been evaluated in monkeys, sheep, pigs, chickens, steers, rats and humans (Bowers et 
al.,1984, Croom et al.,1984, Doscher et al.,1984, Kraft et al.,1984, Malozowski et 
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al.,1991, Bowers et al.,1990, Ilson et al.,1989). GHRP-6 can increase the level of Gh 
mRNA independent of GHRH, and the two together lead to a synergistic activation of Gh 
mRNA (Cheng et al., 1989, Goth et al.,1992). Even though the precise mechanism of 
action of GHRPs is not known, it is postulated that GHRP binding to GHRP receptor 
leads to an increase in intracellular Ca
2+ 
(Akman et al.,1993; Sartor et al.,1985), no 
change in intracellular cAMP (Cheng et al.,1989, Wu et al.,1994) and a possible 
activation of the protein kinase C (PKC) pathway (Cheng et al., 1991; Cheng et al.,1993).  
 
Several other hypothalamic peptides participate in the regulation of Gh, some of them 
having dual functions depending on age, pathological state, site of action, etc. For 
instance, thyrotropin releasing hormone (TRH) is stimulatory in fetal and neonatal stages 
before the somatotropic axis is established or in pathologies such as acromegaly (Cocchi 
et al., 1983; Harvey, 1990), whereas it inhibits GH release by its action on the 
hypothalamus (Cocchi et al., 1983; Müller, 1987). CRH, corticotrophin releasing 
hormone, and neuropeptide Y (NPY) both have an inhibitory effect (Katakami, 1985, 
Ono et al., 1984; McDonald, 1985; Rettori et al., 1990), and both are most likely 
mediated by SST (Katakami, 1985). PACAP, another brain-gut peptide has a pronounced 
role in GH release in fish (Montero et al., 2000; Wong et al., 2000) and amphibians 
(Martinez-Fuentes et al., 1994), somewhat of a lesser effect in birds (Peeters et al., 1998), 
and possibly no effect in mammals (Miyata et al., 1989; Jarry et al., 1992; Sawangjaroen 




Among peripheral gland hormones, glucocorticoid (GC) regulation of Gh gene 
expression has been extensively studied in many vertebrate species. A part of the 
regulation is mediated through GC action on the hypothalamic regulators, GHRH (Seifert 
et al., 1984; Michel et al., 1984) and SST (Holl et al.,1988; Schonbrunn et al.,1982). 
However, GCs can also directly stimulate Gh gene transcription by acting through a 
ligand-dependent transcription factor (Thakore and Dinan,1994). These effects of GCs 
are true for physiologic doses. Physiological concentrations of thyroid hormones are also 
necessary for the maintenance of Gh gene expression (Giustina and Wehrenberg,1995). 
Thyroid hormones act in concert with GHRH by enhancing the effect of GHRH on 
somatotrophs (Martin et al., 1985; Korythko et al.,1997).  
 
Apart from the major regulators of Gh mentioned above, a host of other factors influence 
GH synthesis and secretion in vertebrates. Ghrelin, a stomach peptide hormone, has been 
shown to act as a stimulator of GH in all species. Neurotransmitters such as serotonin and  
norepinephrine, metabolic signals such as glucose and leptin, nonesterified fatty acids, 
nitric oxide, amino acids such as arginine, ornithine, lysine, and tryptophan, have all been 
shown to have specific roles in GH synthesis, secretion and feedback mechanisms, 
detailed explanations of which are beyond the scope of this review (Muller et al., 1999). 
It suffices to say that Gh regulation is a complex process involving numerous players, 
which act in concert with tissue specificity to maintain normal GH supply and function in 




Transcription factor regulation of Gh gene expression 
The regulatory regions of the Gh gene have been identified and characterized in several 
vertebrate species. In the species studied so far, PIT1 is undoubtedly the single most 
important transcription factor regulating Gh gene expression in the anterior pituitary 
somatotrophs. PIT1 is essential for terminal differentiation of cells of the PIT1 lineage 
(thyrotrophs, somatotrophs and lactotrophs) and for gene expression of the hormones 
secreted by these cells, β-subunit of thyroid-stimulating hormone (TSHβ), growth 
hormone (GH) and prolactin (Prl), respectively (Ingraham et al. 1988). Evidence of this 
essential role of PIT1 includes pituitary hypoplasia and lack of detectable levels of the 
hormones in Pit1 mutant mice (Li et al., 1990) and also clinical studies in humans 
(Radovick et al., 2000). However, although necessary, PIT1 is not sufficient to regulate 
somatotroph-specific Gh gene expression. PIT1 interacts with other transcription factors, 
both general and specific, as well as with co-activators to bring about this highly cell-type 
specific gene expression. Several of the cellular factors that bind to and regulate the Gh 
promoter have been identified. Steroid hormone receptors, such as the glucocorticoid 
receptor (GR) and more extensively the thyroid hormone receptor (TR), binding to the 
Gh promoter has been studied, and the results have shown that the regulation of Gh varies 
considerably across species. Other transcription factors, such as Ets-1 (Yang et al., 2010), 
Sp-1 (Melamed et al., 1998), NF-1 (Norquay et al., 2003), Ikaros (Ezzat et al., 2005) and 
Zn finger 15 (Zn-15) (Lipkin et al., 1993) are involved in tissue-specific transcription of 
Gh. The regulation of Gh expression in chickens will be discussed in subsequent sections, 
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and similarities and differences with mammalian species deemed noteworthy in the 
context of current work will be addressed.  
 
Promoter analysis of the Gh gene across species brings out some common features. 
General transcription regulatory sequences, such as the TATA box, are present in 
representative species of all classes (teleosts, amphibians, birds, primate and non-primate 
mammals). In general, the fish species show maximum inter-species variation. Similarly, 
PIT1 and at least one AP site(s) are present in all species examined so far. The 
mammalian and chicken promoters have some similarities in terms of the binding sites 
present, marked by the presence of Sp1 and AP-2 binding sites, cAMP- and vitamin D 
response elements, and thyroid hormone response elements; however, the copy numbers 
and relative locations of these sites vary widely (Chuzhanova et al., 2000).  
Somatotroph differentiation and Gh gene expression in the chicken 
Somatotroph differentiation takes place during the latter half of embryonic/fetal 
development in chickens and rats. In chickens, growth hormone-secreting cells are first 
detected on embryonic day 12 (e12) in the caudal portion of the pituitary gland, and they 
become a significant population around e16 (Porter et al., 1995). Concomitant with this 
increase in abundance, Gh mRNA and protein levels increase and serum GH levels 
become detectable (Harvey et al., 1979). Somatotroph differentiation is a highly 
regulated developmental process requiring the participation of signals emanating both 




















Fig. 2 Schematic representation of regulation of growth hormone in chickens by signals emanating from the 




A blood-borne signal is required for somatotroph differentiation. Anterior pituitary cells 
isolated from e12 to e16 chickens (prior to somatotroph differentiation) fail to 
differentiate into functional somatotrophs in culture in the absence of serum. Serum from 
e16 has the highest potency to induce somatotroph differentiation in cultured cells (Porter 
et al., 1995). Heat-inactivated, but not ether-extracted serum maintains the ability to 
induce differentiation, suggesting the blood-borne factor is a steroid. This signal was later 
found to be the adrenal glucocorticoid, corticosterone (CORT), the level of which is 
known to increase dramatically with the onset of somatotroph differentiation (Morpurgo 
et al., 1997; Jenkins and Porter, 2004). 
 
In both rats and chicks, endogenous thyroid hormone, especially triiodothyronine (T3), is 
necessary for somatotroph differentiation. However, unlike CORT, thyroid hormone is 
ineffective in increasing somatotroph abundance by itself and requires the presence of 
CORT (Liu et al., 2003; Nogami et al. 1997). Also, the effect of T3 is age-dependent, as 
at e20 T3 actually inhibits GH secretion (Liu and Porter, 2004; Jenkins et al., 2007). 
 
Role of Glucocorticoids in somatotroph differentiation 
 
Glucocorticoids (GCs) (cortisol in humans, CORT in rodents and birds) can induce 
premature differentiation of somatotrophs both in vitro and in vivo. Isolated chicken 
pituitary cells and whole rat pituitaries treated with GC show an increase in the number 
of somatotrophs, and these cells are characterized by increased Gh mRNA, protein and 
GH secretory capacity (Hemming et al., 1988;  Morpurgo et al., 1997; Nogami et al., 
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1997;  Dean and Porter, 1999; Liu et al., 2003). GCs show this effect only after the Pit1 
gene is expressed in the anterior pituitary and not before, suggesting the involvement of 
CORT in inducing the differentiation of cells already committed to become 
somatotrophs. GC induction of these committed cells cannot be blocked by a mitosis 
inhibitor, thus ruling out the possibility of CORT increasing the abundance of 
somatotrophs by acting as a mitogen and not a terminal signal (Porter et al., 1995).  
 
Treatment of pregnant rats with dexamethasone (dex), a synthetic glucocorticoid, results 
in premature appearance of GH cells in the corresponding fetuses on e17 and e18, before 
e19 when somatotrophs become a significant population (Nogami and Tachibana ,1993). 
Similarly, in chicken, treatment of e11 embryos with either e16 serum or CORT 
increased somatotroph abundance on e14 (Porter et al., 1995; Dean et al., 1999). 
 
 The mechanism of CORT induction of somatotroph differentiation and Gh gene 
expression is not known; however, the process appears to be indirect. In both rats and 
chickens, the ability of GC to induce somatotroph differentiation and increase Gh mRNA 
can be blocked by protein synthesis inhibitors (Nogami et al., 1997; Bossis and Porter, 
2003). This indicates the potential involvement of intermediary factors in the process. 
The transcription factor PIT1 was the first to be considered a likely candidate induced by 
GC. However, GCs do not increase the levels of Pit1 mRNA, protein or the number of 
PIT1 expressing cells, ruling out the possibility that this factor might be PIT1 (Fu and 
Porter, 2004). Another possible candidate was the GHRH receptor (GHRH-R). In rats, 
GHRH-R levels increase in response to GC in vitro (Nogami et al., 1999). However, the 
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following lines of evidence from chickens rule out the possibility of GHRH-R being 
involved in increasing Gh mRNA in response to CORT. GHRH treatment along with 
CORT stimulated Gh mRNA expression to a level above that obtained with CORT alone, 
but GHRH alone had no effect (Dean and Porter, 1999). GHRH-R stimulates GH 
synthesis and secretion by increasing cellular cAMP levels and by activating protein 
kinase A (PKA) (Anderson et al., 2004). Cells treated with forskolin (which increases 
cAMP levels) and 3-isobutyl-1-methylxanthin (IBMX) and CORT mimicked the levels of 
Gh mRNA achieved with co-treatment of CORT and GHRH (Bossis and Porter, 2003). 
Increased cAMP levels could not induce Gh mRNA in the absence of CORT. Therefore, 
activation of GHRH-R is not an essential step in GC induction of Gh mRNA expression. 
Involvement of PKA and PKC in GC stimulation of Gh gene expression was ruled out by 
use of inhibitors; H-89 and calphostin C, respectively. Blocking the PKA pathway with 
H-89 resulted in obliteration of the synergistic effect of CORT and GHRH, indicating 
that the chicken GHRH-R acts by stimulating PKA. However, H-89 did not block CORT 
induction of Gh (Bossis and Porter, 2003, Porter, 2005). In contrast, treatment of e11 
chicken pituitary cells with inhibitors of specific signaling pathways showed the 
involvement of MEK1/2, p38 MAPK, and Ras signaling pathways (Malkiewicz, 2003; 
Ellestad, 2010). Both Gh mRNA levels and the number of cells expressing GH protein 
were reduced in the presence of these inhibitors. The ability of CORT to activate Gh 
promoter activity in the presence of these inhibitors was also examined, and the results 
confirmed the involvement of MEK1/2, p38 MAPK and Ras signaling (Ellestad and 
Porter, unpublished results).  
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The glucocorticoid receptor 
The cellular actions of GCs are mostly mediated through the glucocorticoid receptor 
(GR), which is a ligand-dependent transcription factor. GR belongs to the family of 
nuclear receptors (NRs), more specifically to a subset of NRs called steroid hormone 
receptors. Other members of this family are the androgen receptor, the mineralocorticoid 
receptor, the estrogen receptor and the progesterone receptor (Mangelsdorf et al.,1995). 
GR is ubiquitously expressed, but the sensitivity of the receptor to its ligand is not 
uniform across organs (Lim-Tio et al., 1997). 
 
GR is characterized by a number of specific functional domains, those responsible for 
dimerization, transactivation, ligand binding and DNA binding (Wurtz et al. 1996, 
Weatherman, 1999). In the absence of ligand, GR is present in the cytoplasm in a 
complex with chaperone proteins. Upon hormonal stimulation, GR dissociates from the 
complex, dimerizes and translocates to the nucleus, where it activates genes by binding to 
glucocorticoid response elements (GREs) in the promoter elements of target genes 
(Dostert and Heinzel, 2004) or represses genes by either binding to negative GREs or by 
binding to other transcription factors (Martens et al., 2001). 
 
More than 1700bp of the 5’-flanking region of the chicken Gh gene has been analyzed 
and functionally characterized (Ip et al. 2004) (Fig. 3). The organization of the proximal 
promoter region of the chicken Gh gene differs from that of the mammalian Gh genes, 











Fig. 3 Schematic representation of the chicken growth hormone promoter. Shown here are the TATA box 
and putative binding sites for thyroid hormone receptor (TRE), PIT1. Note the absence of classical 




in terms of activating and repressing factors employed. The promoter region of the 
chicken Gh gene has two PIT1 binding sites, a proximal site located at -113/-104 and a 
distal site at -541/-533, along with a putative thyroid hormone response element (TRE) at 
-137/-128. A TATA box is located at -24bp. Further functional characterization of the 
two PIT1 binding sites revealed the proximal site to be functional and able to bind PIT1, 
while the distal site was found to be either redundant or repressive, but only in the 
presence of the proximal site. Although no GRE was found, the region between -1727 
and -1467 was found to be GC responsive in induction of Gh (Ip et al., 2004). 
PIT1: A POU-homeodomain transcription factor 
Gh and Prl are two evolutionarily related genes, but they are expressed in phenotypically 
distinct cells within the same tissue. Experiments aimed to elucidate the mechanism 
behind such cell-type specific expression within the same organ identified a nuclear 
DNA-binding protein (initially named PIT1) as a transcription factor regulating both 
genes (Lefevre et al., 1987; Nelson et al., 1988). Promoter deletion analyses and DNase 
protection assays identified proximal and distal PIT1 binding sites as an imperfect 
palindrome with a core consensus A (A/T) (A/T) TATNCAT within the promoter of both 
genes.  The pituitary-restricted expression and the ability to specifically activate Gh and 
Prl made PIT1 a possible positive transcription factor for Gh and Prl gene transcription 
(Nelson et al., 1988; Cao et al., 1987).  
 
Purification of the factor(s) bound to proximal PIT1 binding sites in Prl and Gh 
promoters from rat pituitary G/C cells revealed a doublet of 31kDa and 33kDa (Nelson et 
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al., 1988). Soon after, the rat Pit1 coding sequence was determined to be 873 nucleotides 
long, giving rise to a protein of approx. 33kDa (Ingraham et al., 1988). The in vitro 
translated product also ran as a doublet of the same size as the endogenous protein, and 
they were found to be translated from multiple mature transcripts derived from the same 
gene. Structurally, the amino terminus of this transcription factor was found to be unique, 
but the carboxyl terminus had marked similarity to a homeodomain found in many 
Drosophila and vertebrate regulatory genes (Ingraham et al., 1988).  
 
At about the same time, three other transcriptional regulators, namely, a ubiquitously 
expressed octamer-binding protein Oct-1, a lymphoid tissue specific Oct-2, and a C. 
elegans developmental regulator unc-86 were identified and found to contain a similar 
carboxyl terminus. Due to this sequence similarity they were thought to belong to a 
related family of transcription factors which was thereafter named the ―POU family of 
transcription factors‖ (named after PIT1, Oct-1/2, unc-86) (Sturm et al., 1988).  
 
The POU proteins show remarkable sequence similarity over an approximately 160 
amino acid length of sequence. The POU domain that characterizes this family can be 
subdivided into two subdomains: a C-terminally located POU homeodomain and an N-
terminal POU-specific domain. The N-terminal domain (73-80 amino acids depending on 
species) is the transactivation domain required for transactivational properties of PIT1. 
The transactivation domain is characterized by a high percentage of serine and threonine 
residues but is otherwise not highly conserved (Theill et al., 1989). 
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The homeodomain shares sequence similarity with other homeodomain proteins; 
however, the extent of similarity between the members of this family is higher than that 
between a POU factor and other homeodomain factors. This POU homeodomain (POU-
HD) is about 60 amino acids in length, containing a tryptophan and a phenylalanine 
residue that are strictly conserved among all POU members and a cysteine that is not 
found in other homeodomain proteins except the POU proteins (Herr et al., 1988).  
 
Separated from the POU-HD by a linker of variable length and composition is the second 
POU sub-domain of about 80 amino acids. This domain is the most unique feature of this 
family of transcription factors and is referred to as the POU-specific domain (POU-S). 
Once again, there is high similarity between the members of this family in this domain. 
This domain can be further subdivided into two regions of sequence similarity that are 
higher than in any other region among the four members, with the exception of Oct-1: 
Oct-2 (Reviewed by Herr et al., 1988). The function of the hinge region is not known, but 
it may be non-functional, as deletion of the hinge region did not affect PIT1 activation of 
the TSHβ promoter (Gordon et al., 2002).  
 
Both the POU-HD and POU-S domains are involved in DNA binding. Low affinity 
binding of PIT1 to its target region can be achieved by POUHD, but the POUS is 
required for site recognition and high affinity binding by virtue of a predicted alpha-
helical structure within the region (Ingraham et al., 1990). Even though the N-terminal 
domain is primarily involved in transactivation of target genes, some residual 
transcriptional activation is also associated with the POUHD (Theill et al., 1989, 
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Ingraham et al., 1990). PIT1 is found in a monomeric state in solution, but usually binds 
DNA as a dimer. Protein-protein interactions with other transcription factors/coregulators 
are also mediated via the POUS domain (Theill et al., 1989). 
Regulation of target genes by PIT1 
The well-studied targets of PIT1 include Gh, Prl, TSHβ and GhRH-R. These target genes 
contain one or more PIT1 binding sites in their promoter regions. The sequence of the 
PIT1 binding sites has been determined in mammals [(A/T)(A/T)(A/T)TATNCAT] 
(Nelson et al., 1988) and in avian/teleost species [(A/T)NCTNCAT] (Ohkubo et al., 
1996). However, given the redundancy of the PIT1 binding site, it is very likely that 
several other pituitary genes are regulated by PIT1 at the transcriptional level. Indeed, 
results from our lab have shown that Ras-DVA is a novel PIT1 regulated gene (Ellestad, 
2010). In addition, PIT1 autoregulates itself (Chen et al., 1990;  Rhodes et al., 1993).  
 
Multiple lines of evidence suggest a role of PIT1 in pituitary development and regulation 
of hormones secreted by cells of the PIT1 lineage. Pit1 mRNA and protein are expressed 
in the anterior pituitary before the differentiation of these cell types (Dolle et al., 1990; 
Simmons et al., 1990). Mutations in the Pit1 gene lead to severe pituitary hypoplasia, 
absence of the hormone producing cells, and complete lack of hormone gene 
transcription (Wilson and Wyatt, 1986; Radovick et al., 1992). Mice carrying mutations 
in the Pit1 gene show dwarfism and severely reduced somatotrophs, lactotrophs and 
thyrotrophs. The Jackson dwarf mice are characterized by a gross alteration of the Pit1 
gene resulting from an insertion or inversion of a >4kb piece of DNA. The Snell mutant 
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has a point mutation in the POUHD resulting in a substitution of the tryptophan residue at 
position 261 with cysteine (Li et al., 1990). Mutations in Prop-1, a paired-like 
homeodomain protein required for Pit1 gene activation and regulation also lead to 
dwarfism and absence of the cells of the PIT1 lineage (Sornson et al., 1996). In all the 
mutants, levels of PIT1 are nearly undetectable (Li et al., 1990; Sornson et al., 1996). 
Knocking down Pit-1 expression by antisense oligonucleotides blocks Gh and Prl 
transcription along with inhibition of proliferation of somatotroph and lactotroph cell 
lines (Castrillo et al., 1991). In teleosts, zebrafish Pit1 mutant lacking 55 amino acid 
residues due to an internal truncation resulting from alternative splice site-usage shows 
severe dwarfism and lack of the three pituitary cell types (Nica et al., 2004). 
 
The regulation of cell-type specific expression of target genes by PIT1 has always been a 
conundrum. PIT1 is expressed in 3 cell types of the anterior pituitary; however, even 
within the cells of PIT1 lineage, there is specificity of hormone production. This cell type 
specificity is not just because the chromatin conformation is not conducive to 
transcription, because both in corticotrophs and in non-pituitary cell lines (Ingraham et al, 
1988), where, for instance, the Gh promoter should be in closed conformation, 
transfected Pit1 brings about expression of Gh. However, in lactotrophs, Gh gene 
transcription does not take place even in the presence of PIT1. In the lactotroph-derived 
cell line 235-1 (Nelson et al., 1988), transfected Gh promoter is not activated by PIT1 
(Ingraham et al., 1992), suggesting the presence of factors that either occupy the PIT1 
binding site itself or the immediate vicinity, and/or modifies PIT1 in such a way that it is 
unable to bind Gh promoter PIT1 binding sites and/or recruit other essential transcription 
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factors, thus providing a negative regulation. An alternative mode of this regulation could 
be that factors otherwise ubiquitous are specifically absent from lactotrophs (Crenshaw et 
al., 1989).  
 
Regulation of GHRHR by PIT1 has been studied in mammals, but not in any other 
vertebrate class. The human and rat GHRHR gene promoters lack a TATA box, and have 
multiple PIT1 binding sites. Other transcription factor binding sites common between the 
two species are for estrogen receptor (ER) and CREB (Petersenn et al., 1998; Miller et 
al., 1998; Iguchi et al., 1999; McElvaine et al., 2007). Out of the multiple PIT1 binding 
sites present, usually a few are functional and even fewer contribute significantly to 
regulation of transcription. The purpose of having multiple sites is not known. In humans, 
GHRHR gene transcription is regulated by GCs, even though the 5’flanking region lacks 
a classical GRE. In rat, two GREs along with a PIT1 binding site and an internal silencer 
region make up the glucocorticoid response unit. It is hypothesized that PIT1 binding to 
its element leads to release of an unknown factor from the silencer, allowing GR to bind 
to the GRE (Nogami et al., 2005). 
 
TSHβ gene expression is regulated positively by TRH (Steinfelder et al., 1992) phorbol 
esters (Haugen et al., 1993) and forskolin (Kim et al., 1993), and negatively by thyroid 
hormones and estrogen (Steinfelder et al., 1992, Nagayama et al., 2008). The 5’flanking 
region of this PIT1 regulated gene has been characterized in mammalian species (human, 
mouse, rat) (Steinfelder et al., 1992; Haugen et al., 1993; Mason et al., 1993) and 
goldfish (Sohn et al., 1999), but information from other groups of vertebrates is lacking. 
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In humans, 128bp of the 5’-flanking region is sufficient for the TRH response. This 
region has multiple functional PIT1 binding sites (Steinfelder et al., 1992). TRH 
induction leads to increased cAMP, but the effects of cAMP are likely mediated through 
PIT1, as there is no cAMP response element (CRE) in this region. Also, the effect can be 
mimicked in non-pituitary cell lines only in the presence of transfected PIT1 (Steinfelder 
et al., 1992). In rat, PIT1 binds to the minimal promoter required for TRH responsiveness 
(Mason et al., 1993). In all species studied, PIT1 is necessary but not sufficient to 
facilitate thyrotroph-specific gene expression of TSHβ. While PIT1 binding to DNA is 
critical, there was evidence of the involvement of another factor, later identified to be 
GATA2 (Gordon et al., 1997). Both PIT1 and GATA2 bind to the TSHβ promoter. In 
mouse, 5’-PIT1 and 3’GATA2 binding sites along with 16bp of spacer make up a 
composite unit. The spacer contains additional putative overlapping PIT1 and GATA2 
binding sites, and the sequence of the spacer is functionally important. When only the 
spacer is mutated with the flanking PIT1 and GATA2 binding sites left intact, there is 
markedly reduced binding of both transcription factors and almost no formation of the 
ternary complex (Gordon et al., 2002). It is hypothesized that binding of one factor 
causes the DNA to bend and attain a conformation that permits and facilitates the binding 
of the other factor. Also, PIT1 and GATA2 physically interact with each other; the POU 
homeodomain of PIT1 interacts with the zinc finger domain of GATA2 (Gordon et al., 
2002). PIT1 also interacts with CREB binding protein (CBP) on the TSHβ promoter, but 




Prl is a peptide hormone with diverse functions and expression in several tissues, 
including the lactotrophs of the anterior pituitary gland (reviewed by Bole-Feysot et al., 
1998). In humans, transcription of prolactin involves 2 independent promoters: proximal 
5kb involved in pituitary-specific expression and a more distal promoter for regulation in 
other tissues (Berwaer et al., 1991, 1994). Dopamine negatively regulates prolactin 
(McLeod, 1969; Elsholtz et al., 1991). Factors that stimulate Prl include TRH, oxytocin, 
VIP, epidermal growth factor (EGF), estradiol and phorbol esters (Day and Maurer, 
1989). Several of these pathways lead to increased cellular cAMP levels in both 
mammals and birds, and the cAMP effect is thought to be mediated by PIT1 if no CRE 
are found in the minimal promoter sufficient for activation of the Prl promoter in 
response to the stimulus (Peers et al., 1991). Also, PIT1 may or may not need to be 
phosphorylated to bring about the effect, suggesting the involvement of other factor(s) 
that interact with PIT1 in mediating the effect. The interacting factor(s) of PIT1 in 
regulating the Prl gene are several, including, but not limited to, Ets-1, GR, and Oct-1. A 
composite PIT1/Ets-1 binding site in the rat Prl promoter is required for mediating the 
induction of Prl by several stimulatory factors (Howard and Maurer, 1995; Bradford et 
al., 1997). PIT1 physically interacts with GR to inhibit human Prl transcription (Nalda et 
al., 1997), while PIT1 heterodimerizes with Oct-1to produce synergistic activation of the 
rat Prl promoter (Voss et al., 1991; Verrijzer et al., 1992).  
 
PIT1 is the major regulator of Gh gene expression by pituitary somatotrophs, but other 
nuclear factors are essential for the highly cell-type specific expression of GH. The Zn 
finger transcription factor Zn-15, binds to so-called ―Z boxes‖ in the rat Gh promoter and  
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in other species and regulates Gh transcription, and a mutation in the Zn-15 binding site 
leads to a notable reduction of GH synthesis (Lipkin et al., 1993). GC induction of Gh is 
a well-studied phenomenon, and in most species the effect is mediated through GR 
binding to GREs in the Gh promoter. In species where a canonical GRE is absent, GR is 
thought to mediate its effect by GR tethering to other protein(s) already present on the Gh 
gene promoter. GHRH induction of Gh is known to increase intracellular cAMP levels 
and activation of the PKA pathway. The exact target of PKA is not known, nor has the 
mechanism leading to increased Gh been elucidated. PIT1 is thought to be involved in the 
cAMP-induced response, whereby PKA phosphorylates PIT1, leading to an altered 
conformation and increased binding to the Gh promoter. However, evidence available 
showing the requirement for PIT1 phosphorylation has been conflicting. There are two 
hypotheses: in one scenario, increased cAMP leads to CREB phosphorylation and 
activation, CREB binding to CREs present in the promoter and activating transcription. 
In the absence of functional CREs, however, it is hypothesized that the mechanism is 
CREB-independent, and according to the alternative hypothesis, activated PKA instead 
leads to phosphorylation of CREB-binding protein (CBP), which can then act as a co-
factor of PIT1 (Cohen et al., 1999). PIT1 dependent negative regulation of Gh is 
mediated by activin by reducing PIT1 binding to Gh promoter (Struthers et al., 1992). 
Pit1 mutations as a cause of human pathologies 
A tightly regulated spatiotemporal pattern of transcription factor expression is essential 
for initiating and maintaining the ontogeny of the pituitary gland and maintaining the 
pituitary cells in their state of terminal differentiation. In general, factors expressed late 
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during pituitary development are more pituitary-specific than ubiquitous. Mutations of 
these late-expressed pituitary specific transcription factors, especially Prop1 and Pit1 are 
the most common causes of combined pituitary hormone deficiency (CPHD) (Cohen et 
al., 1996). Phenotypes of patients of Pit1 mutations are similar to those of dwarf mice. 
These mutations affect somatotroph differentiation, and as a result, dwarfism is the most 
common phenotype associated with Pit1 mutations (Pfäffle and Klammt, 2011). Patients 
with a mutation in Pit1 show complete lack of Gh and Prl, and a loss of TSH is common 
but not always found. This phenomenon can have 2 explanations; either the thyrotrophs 
arise independently of PIT1 expression, and/or since the PIT1 regulation of target genes 
is highly context dependent, it is possible that PIT1 might primarily affect Gh and Prl 
compared to TSHβ (Drolet et al., 1991; Lin et al., 1994).  
 
In humans, mutations of Pit1 have been found in 2 introns and all exons (except exon 2). 
Some of the dominant negative mutations are Ser179Arg, Lys216Glu and Arg271Trp 
(Cohen et al., 1999; Miyata et al., 2006; Radovick et al., 1992). Of these, the last two are 
sporadic in nature. Arg271Trp, although located in the homeodomain, does not interfere 
with DNA-binding, because it is immediately 3’ of the two alpha helices required for 
binding. However, even if it binds DNA just like the wild type, it does not transactivate 
the target gene promoters, but the mechanism behind the inactivity is not known 
(Radovick et al., 1992). In the case of dominant negative mutations, patients who are 
heterozygous carriers may or may not manifest CPHD, and the extent of manifestation 
seems to vary (Reynaud et al., 2004). Also, the lack of transactivation by the dominant 
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negative mutants is not always reproducible in vitro, thus making it an active area of 
clinical research (Pernasetti et al., 1998).  
Pit1 and production traits 
Since the well-studied PIT1 regulated genes, Gh, Prl and TSHβ, are all involved in 
metabolic functions such as energy balance and homeostasis, it was tempting to predict a 
role of PIT1 in production traits. Indeed, several studies have been done in agricultural 
animals to identify polymorphisms associated with agricultural performances. Single 
nucleotide polymorphisms of Pit1 have been identified as genetic markers for 
reproductive (fertilization) rate in cattle (Khatib et al., 2009). Agricultural traits such as 
body weight, wither height (Zhang et al., 2009), milk yield and duration of reproductive 
life (Huang et al., 2009) are a few others that are influenced by PIT1. Similarly, in pigs, 
birth weight (Song et al., 2007), fat thickness (Franco et al., 2005), growth, meat quality 
and carcass composition (Brunsch et al., 2002) are correlated with Pit1 polymorphisms 
which can be either in the introns or exons. Cashmere wool production in goats is 
determined by a polymorphism located at the 3’-UTR of Pit1 (Lan et al., 2009).  In 
chickens, growth traits such as growth rate, but not carcass composition or fat content are 
associated with Pit1 polymorphisms (Jiang et al., 2004; Nie et al., 2005). 
Alternative forms of Pit1 
Isoforms, by definition, are structurally and functionally similar proteins which differ 
from each other in their amino acid sequence. Isoforms may arise from the same gene or 
from different genes. When isoforms are derived from the same gene, they may be the 
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result of alternative transcription initiation sites, alternative translation initiation sites, 
alternative splicing or any combination thereof. All three mechanisms are well 
established modes of genome expansion. 
 
Alternative forms of Pit1 have been reported in almost all species where PIT1 expression 
has been studied (Voss et al., 1991; Morris et al., 1992; Theill et al., 1991; Haugen et al., 
1994; Kurima et al., 1998; Tanaka et al., 1999; Van as et al., 2000; Bastos et al., 1991). 
These isoforms arise as a result of alternative translation and/or alternative splicing. 
There is considerable variation in the number and types of isoforms reported across 
species, but it is entirely possible that not all isoforms from a particular species have been 
identified. 
 
As mentioned previously, PIT1 protein was seen to run in gels as a doublet of 33KDa and 
31KDa in extracts from both murine and human primary tissues. Pulse-chase experiments 
showed that there was no precursor-product relationship between the two, and the 
presence of downstream in-frame AUG start codons in the Pit1 sequence gave rise to the 
possibility that these two bands represented alternative forms of PIT1. Site-directed 
mutagenesis proved this hypothesis to be true. Both the isoforms could bind DNA 
sequences equally well, and both isoforms could transactivate the rat Prl promoter in CV-
1 (non-pituitary) cells, which was surprising because the shorter isoform was lacking 27 
amino acids from the transactivation domain. The relative levels of the 33- and 31KDa 
isoforms were roughly 2:1; however, how these levels are regulated in pituitary cells is 
not known (Voss et al., 1991; Ingraham et al., 1991). Soon afterwards, an alternatively 
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spliced isoform was discovered. This isoform differed from the original PIT1 in having a 
78-nucleotide exon present at position 142, immediately after exon 1. This alternative 
form was name PIT1a. This isoform differed considerably in both abundance and 
function; the transcript levels of this longer isoform were approximately 1/7
th
 of Pit1, and 
this isoform showed minimal to no transactivation of the Prl promoter in Chinese hamster 
ovary (CHO) cells, even though it bound equally well to PIT1 binding sites of this 
promoter as the shorter 33kDa form. However, the alternatively spliced protein product 
was not detected in CHO cells by overexpression, and only minimal detection was found 
in rat pituitary cells. Thus, this isoform was thought to be either translated less efficiently 
or degraded at a more rapid rate. The ability of this isoform to regulate the Gh promoter 
even more actively than PIT1 in both pituitary and non-pituitary cells has been reported 
by all groups except one (Morris et al., 1991; Theill et al., 1992; Konzak and Moore, 
1992).  
 
A thyrotroph-specific isoform, Pit1T, arising as an alternatively spliced form was 
detected in the mouse. This isoform has an additional 14 amino acids at the 5’-end of 
exon 2 and is required, along with PIT1, for activation of the TSHβ promoter in 
thyrotrophs (Haugen et al., 1993). Identification of PIT1T raised the number of isoforms 
in mouse to four. However, PIT1T was not detected in humans and rhesus monkey.  
Conclusion 
Somatotroph differentiation and Gh gene expression are tightly regulated processes 
requiring interaction among a large number of transcriptional regulators and signaling 
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pathways.  Adrenal glucocorticoids are essential for both processes, and act in concert 
with other peripheral hormones. PIT1, the transcription factor necessary for the 
processes, is involved in the differentiation of cells of the PIT1 lineage, and also regulates 
other pituitary hormones. However, PIT1, even though necessary, is not sufficient, and 
requires participation of other general and specific transcription factors. Alternative 
forms of Pit1 have been reported in numerous species, but the functional implications of 
having several isoforms with similar functions are not clear. Studies aimed at functional 
characterization of PIT1 isoforms in avian species are particularly lacking. The present 
study was aimed at characterizing the chicken PIT1 isoforms for their ability to regulate 















Chapter 2: Regulation of chicken growth hormone by PIT1 isoforms 
Introduction 
Growth hormone (GH) is a peptide hormone produced in specialized cells called 
somatotrophs in the anterior pituitary gland. Even though GH has a diverse range of 
functions in essential physiological processes, regulation of bone and muscle growth and 
metabolism are the main functions associated with it. These particular functions make 
regulation of somatotroph differentiation and GH synthesis an active area of research in 
agriculture and human medicine.  
 
In broiler chickens, GH levels are high post-hatch. Exogenous GH administration when 
endogenous levels are high has no effect on chicken growth. However, in ovo 
administration of GH during embryonic development leads to increased growth post-
hatch (Blumenthal, 1954), suggesting establishment of a growth threshold in the egg. 
Current work in our laboratory focuses on elucidating how extrapituitary signals are 
involved in the regulation of somatotroph differentiation and GH synthesis in the 
embryonic chicken. Chickens have the dual advantage of being agriculturally important 
as well as model animals for biomedical research. In addition, chickens are an excellent 
model system for studies of embryonic development and endocrine regulation because i) 
it is relatively cheap to obtain a large number of samples for study; ii) the precise timing 
of development of a large number of embryos can be synchronised with relative ease; iii) 




More than a decade of research by our laboratory and by others has contributed 
significantly to dissecting the mechanism of somatotroph differentiation and Gh gene 
expression in chickens. Somatotrophs first appear on embryonic day 12 (e12) during 
development, and become a significant population by e16 (Porter et al., 1995). A blood-
borne extra-pituitary signal is required for somatotroph differentiation and final 
maturation. The signal was identified to be the adrenal glucocorticoid corticosterone 
(CORT) (Morpurgo et al., 1997), which can induce premature differentiation of 
somatotrophs at e11 (Dean and Porter 1999; Jenkins et al., 2007). CORT induction of 
somatotroph differentiation involves both type I mineralocorticoid receptor (MR) and 
type II glucocorticoid receptor (GR) (Bossis and Porter, 2004).  
 
Mechanisms underlying CORT induction of Gh gene expression are largely unknown. 
However, the process seems to require ongoing protein synthesis, as suggested by the 
delay (~ 4hr) between CORT treatment and Gh induction and evidenced by inhibition of 
the process by cycloheximide (Bossis and Porter, 2003). Also, lack of functional GREs 
(glucocorticoid response elements) in 10kbp upstream and 5kbp downstream of the 
chicken Gh (cGh) gene suggests the CORT effect is indirect. Additional features of this 
pathway include involvement of ras and possibly MEK1/2 pathways (Ellestad, 2010) and 
chromatin remodeling at the cGh promoter (Narayana, 2011).  
 
The POU-homeodomain transcription factor PIT1 is essential for Gh gene expression. 
Even though the intermediary factor involved in CORT-induction of cGh synthesis is not 
PIT1, this transcription factor is essential for pituitary specific GH expression in all 
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vertebrate species. PIT1 also regulates expression of other genes in the pituitary, namely 
prolactin (Prl), β-subunit of thyroid-stimulating hormone (TSHβ) and growth hormone-
releasing hormone receptor (GHRH-R).  
 
Pit1 gene structure and function have been conserved across vertebrate species. 
Mammalian Pit1 comprises 6 exons and 5 introns, and avian/teleost Pit1 has 7 introns 
due to the presence of a unique 38 amino acid exon (designated 2a for avian species) 
located between exon 2 and exon 3 (Van as et al., 2000). When compared with other 
avian species, chicken PIT1 shows 97% sequence similarity with turkey PIT1, 93% with 
mallard duck and 89% with zebra finch. Significant homology was also observed with 
non-avian species such as mouse (84%) and Carolina anole lizard (81%). The differences 
among species is mostly located in the N-terminal region, while the C-terminal POU 
domain shows maximum conservation. 
 
Variant forms of PIT1 have been identified in several species that arise by alternative 
transcription, translation and/or splicing. The first report of a variant form was in rat, 
where PIT1 was seen to migrate in a gel as a doublet of 33KDa and 31KDa. The shorter 
isoform arose by translation initiation at a downstream in-frame AUG codon and lacked 
the first 27 amino acid residues present in the 33KDa variant, but did not differ in its 
ability to activate the Prl promoter in CV-1 cells (Voss et al.; 1991). The second 
alternative form in mammals, identified in the same year (Morris et al.; 1991, Theill et 
al.; 1992) arose by alternative splicing and possessed a short exon of 26 amino acids 
inserted after exon 1 in the transactivation domain. This isoform was termed PIT1a by the 
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authors, and was shown to be unable to activate rat Prl promoter in CHO cells. Soon 
afterwards, this isoform was also reported by Theill et al., (1992) in rats and was unable 
to activate PIT1 and Prl, while retaining its ability to activate Gh. Later works (Konzak 
and Moore, 1992) showed PIT1a (subsequently named PIT1β) to be a dominant negative 
repressor of Prl in pituitary cells. However, PIT1β is a repressor of PIT1 function only in 
pituitary cells; in non-pituitary cells, it actually potentiates a greater activation of rPrl 
promoter by the PKA pathway (Diamond et al., 1999). Another mammalian species 
where multiple isoforms have been identified and characterized is the sheep (Bastos et 
al., 2006), and this is the only report of characterization of all known isoforms (PIT1α, 
PIT1β, PIT1γ, and PIT1δ) of PIT1 in an agricultural species for their ability to activate 
the rat Prl promoter in HeLa cells. A thyrotroph-specific isoform, PIT1T, reported only in 
a few mammalian species, is known to activate the TSH-β promoter both alone and 
synergistically with PIT1 in non-thyrotroph pituitary cells (Haugen et al., 1994). In 
general, the variants differ from each other in their N-terminal transactivation domain, 
while the C-terminal POU domain is conserved among the isoforms in most species.  
 
Among avian species, 3 turkey PIT1 variants were reported by Kurima et al. (1998). 
These authors designated the avian PIT1 as PIT1* to differentiate from mammalian PIT1. 
tPIT1beta* (turkey PIT1beta) was structurally similar to mammalian PIT1a in having 
arisen by alternative splicing and hence including a beta-specific exon encoding 28 amino 
acids (compared to 26 amino acids in mammals). The identification of tPIT1W* by these 
authors was the first report of a unique avian-specific isoform arising by use of a 
transcription start site in intron1 followed by inclusion of the beta-specific exon.  The 
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presence of PIT1 variants in chicken was first reported by Tanaka et al. (1999). However, 
this report showed only the PIT1* and PIT1W isoforms in layer chickens. Later, Van as 
et al. (2000) reported the presence of all three isoforms, ggPIT1* (Gallus gallus PIT1), 
ggPIT1beta, and ggPIT1W* from Hybro G broiler strains (Fig. 4). Their findings also 
matched the turkey isoforms in their relative abundance, with PIT1* being most 
abundant, PIT1W* of intermediate abundance and PIT1beta* being least abundant. They 
also adopted the nomenclature PIT1α for the canonical form, PIT1β for the derivative of 
PIT1α with the β-specific exon, and PIT1γ for the equivalent of PIT1W* of Kurima et al. 
(1998), and this nomenclature will be followed in this report.  
 
In fish, Pit1 has been cloned so far in chum salmon (Ono and Takayama, 1992), rainbow 
trout (Yamada et al., 1993), Chinook salmon (Majumdar et al., 1996), Atlantic salmon 
(Lorens et al., 1996), gilthead seabream (Martinez-Barbera et al., 1997), ayu (Chiu et al., 
2002) and goldfish (referenced in Ip et al., 2004). In all fish species for which Pit1 has 
been cloned, only one variant has been identified. Chiu et al. (2002) tested the ability of 
ayu PIT1 to activate the zebrafish Gh promoter, and it was found that PIT1 activated 
zebrafish Gh promoter in NIH3T3 cells.  
 
Even though multiple isoforms are found across many vertebrate species, the functional 
implications of having multiple isoforms are not yet fully known. Substantial research by 
the laboratory of Gutierrez-Hartmann in elucidating the function of the PIT1β in general 
and of the β-specific exon in particular in relation to the regulation of Prl has shown that 








Fig. 4 Chicken Pit1 gene and isoforms. (A) Chicken Pit1 comprises of 7 exons and 6 introns, shown in (A). 
Region in bold encode the transactivation domain. The avian specific exon is numbered 2a. (B) Chicken 
Pit1 isoform mRNAs. Alternative forms arise by using alternative transcription initiation and alternative 
splicing. β denotes 28amino acid insertion. Arrows denote the positions of primers used by authors in their 




dominant negative repression of Prl in pituitary cells (Diamond and Gutierrez-Hartmann, 
1996). These same sequences make PIT1β a more potent PKA-mediated activator of Prl 
in non-pituitary cells (Diamond et al., 1999). The same group later showed that the 
repression of Prl in pituitary cells is brought about by chromatin modification 
(specifically, reduction of acetylated state of histone H4) by 5 hydrophobic residues 
present in the β-domain (Diamond and Gutierrez-Hartmann, 2000) and also by inhibiting 
CREB-binding protein (CBP) recruitment to the Prl promoter (Ferry et al., 2005).  
Genes regulated by PIT1 are characterized by the presence of one or more PIT1 binding 
site(s) in the proximal promoter. The cGh promoter has two avian-specific PIT1 binding 
sites at location -113/-104bp (proximal) and -541/-533bp (distal). Activation of this 
promoter was PIT1 dependent and of the two sites, only the proximal has been shown to 
be functional in PIT1 binding by mutational analysis (Ip et al., 2004). 
 
Even though a monomeric configuration is favored in solution, PIT1 is known to bind 
DNA as either a homodimer or a heterodimer. The bipartite structure of the PIT1 DNA-
binding region consisting of a POU-homeodomain and POU-specific domain (POU-HD 
and POU-S, respectively) separated by a linker gives POU proteins the flexibility to 
orient themselves in various configurations on DNA. This flexibility makes it possible for 
PIT1 to regulate target genes in conjunction with other regulatory factors in various cell 
types. X-ray diffraction studies show that PIT1 contacts very few base pairs of the DNA, 
and that the two components of a dimer can bind to perpendicular faces of DNA by 
altering the spacing between them. In this respect, PIT1 differs from Oct-1, in which the 
POU-HD and POU-S bind on opposite faces of the DNA element (Jacobson et al., 1996).  
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PIT1 was shown to bind as a monomer and dimer to Prl and GH binding sites, 
respectively (Holloway et al., 1992). However, this result is not in agreement with later 
work by Sporici et al., (2005). Apart from structural studies, PIT1 homo- and hetero-
dimerization has been demonstrated by GST- pull down assays and gel-shift assays with 
both wild type and dimerization-deficient mutants (Ingraham et al., 1990, Sporici et al., 
2005).  
 
The promoter of the Gh gene has been characterized in several species, including human, 
mouse, dog, cow, rat, chicken and several fish species, and the characteristic features that 
are similar or distinct among these vertebrates have been discussed in the literature 
review. One aspect of Gh regulation that will be reiterated here is that GH synthesis and 
secretion are regulated by signaling pathways leading to elevated intracellular cAMP 
levels. If the Gh promoter in question contains functional cAMP response element (CRE) 
motifs, the effect is most likely mediated via activated protein kinase A (PKA), which 
phosphorylates CREB (CRE-binding protein), leading to CREB binding to CRE and 
recruiting CREB-binding protein (CBP) (Chrivia et al., 1993; Arany et al., 1994; Kwok 
et al., 1994) . CBP regulates transcription by its histone acetyl transferase (HAT)-activity 
by interaction with the basal transcription machinery (Ozryzko et al., 1996; Kee et al., 
1996). However, in the absence of functional CRE motifs, as is the case of chicken Gh, 
rat Gh and several other cAMP-regulated promoters, the mechanism is thought to be 
CREB-independent, involving direct interaction of CBP to specific transcription factors 
(in the case of Gh, PIT1) (Gonzalez and Montminy, 1989; Chawla et al. 1998, Zanger et 
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al., 1999). Surprisingly, in spite of the presence of functional CREs, cAMP regulation of 
the human Gh promoter is CREB-independent (Cohen et al., 1999).  
 
Since almost all target genes of PIT1 are activated by signals that involve activation of 
kinases, a pertinent question to ask was if PIT1 is a target of phosphorylation. Initial 
investigations identified two threonine residues in the PIT1 homeodomain (Thr-219, Thr-
220) and a serine residue (Ser-115) of rat PIT1 as targets of phosphorylation (Kapiloff et 
al., 1991). Among these residues, Thr-220 was initially determined, and later confirmed, 
to be the predominant site (Howard and Maurer, 1994). Phosphorylation of PIT1 at Thr-
220 altered PIT1 binding to proximal and distal binding sites on the Gh and Prl 
promoters, as well as decreased dimerization of PIT1 on some of them. Altered binding 
and dimerization was attributed to altered conformation of PIT1, brought about by 
phosphorylation. Steinfelder et al. (1992) reported similar results for phosphorylation of 
PIT1 by TRH and cAMP for the activation of the human TSHβ promoter. In all cases, the 
signaling pathways involved were PKA and PKC, and sequences immediately upstream 
of the PIT1 binding sites were thought to dictate binding of phosphorylated PIT1. 
However, PIT1 phosphorylation mutants, in which all three phosphorylation sites were 
mutated to alanine, retained most of the transactivational properties of wild type PIT1 to 
activate the rat Prl and Gh promoters in HeLa cells (Fischberg et al., 1994). Similarly, it 
was shown that even though PIT1 was essential for activation of the Prl promoter by 
cAMP, PIT1 phosphorylation was not required (Okimura et al., 1994), suggesting that 
other phosphorylation-dependent components may be involved in the process. Caelles et 
al. (1995) suggested a mitosis-specific phosphorylation of PIT1 by a cell-cycle specific 
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kinase. Such specific phosphorylation is believed to be required for PIT1-dependent 
proliferation of cells of the PIT1 lineage. Subsequent identification of c-fos as a phospho-
PIT1 regulated gene (Gaiddon et al., 1999) lends traction to a role of PIT1 
phosphorylation in cell cycle regulation.  
 
While some body of knowledge exists regarding PIT1 isoform-specific regulation of the 
Prl promoter, not much is known about the Gh promoter. For instance, it is not even 
known what other general or specific factors interact with PIT1 to regulate cell-type 
specific expression of the Gh gene. Recent results from our laboratory have suggested the 
involvement of Ets-1 as a regulator of CORT-induced Gh gene expression (Knubel, 
2010). At the time this project was started, PIT1 isoforms had not been functionally 
characterized in any avian species. Therefore, we decided to characterize the chicken 
PIT1 isoforms for their ability to regulate the cGh promoter. Our specific objectives 
included:1) Define the transcription start site of all chicken Pit1 isoforms; 2) Demonstrate 
that all known isoform mRNAs can be translated into functional proteins; 3) Determine 
the sub-cellular localization of the isoforms; 4) Determine which, if any, of the known 
isoforms regulate the chicken Gh promoter; 5) Demonstrate PIT1 isoform protein binding 
to the cGh promoter; 6) Investigate the effects of simultaneous expression of multiple 
isoforms on activation of the cGh promoter; 7) Determine if the isoforms bind DNA as 
homo- or heterodimers; 8) Identify which, if any of the isoforms interact with CBP; and 
9) Determine if PIT1 is phosphorylated in response to CORT in chicken embryonic 
pituitary cells. Successful completion of this project will be the first report of PIT1 
isoform-specific regulation of a gene regulating agriculturally important traits in an 
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agriculturally important avian species and enrich our knowledge of regulation of Gh gene 
















Materials and methods 
Animal use 
Broiler (Ross x Ross) chicken eggs, when used, were obtained from Allen’s Hatchery 
(Seaford, DE). Embryonated eggs were incubated at 37.5°C in a humidified incubator 
(GQF Manufacturing, Savannah, GA) with rotation every hour. The day that the eggs 
were placed in the incubator, was designated e0, and eggs were removed on various 
stages of development during the 21 day incubation period according to experimental 
requirements. All animal use protocols were approved by the Institutional Animal Care 
and Use Committee (IACUC) of the University of Maryland. For some experiments, cells 
from several embryos were pooled depending on the number of cells required. 
Cell Culture and Transfections 
The anterior pituitary gland of the embryos was removed using a dissecting microscope 
and dispersed to single cells using trypsin digestion and mechanical agitation as described 
(Porter et al., 1995). For endogenous total protein extraction, cells were allowed to attach 
to poly-L-lysine coated cell culture plates overnight. Treatments, if any, were applied 24 
hr after the cells were plated. For transient transfection experiments, cells were 
transfected following dispersion, plated on poly-L-lysine coated plates and allowed to 
express the transfected gene. Dispersed chicken embryonic pituitary cells were 
maintained at 37.5°C/5% CO2 atmosphere in Dulbecco’s modified Eagle’s 
medium:Ham’s nutrient mixture F12 (DMEM/F12) without serum, supplemented with 
0.1% BSA, 100U/ml penicillin, and 100μg/ml streptomycin, and 5μg/ml human insulin. 
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Leghorn Male hepatoma (LMH) cells [American Type Culture Collection (ATCC), 
Manassas, VA], a chicken carcinoma cell line, were maintained in Waymouth’s medium 
supplemented with 10% fetal bovine serum (FBS) with 100U/ml penicillin and 100μg/ml 
streptomycin in a humidified incubator at 37.5°C and 5% CO2 atmosphere. Cells were 
split by recovering with 0.25% trypsin/ 0.03% ethylenediamine tetraacetic acid (EDTA) 
when confluent and plated in cell culture flasks (Corning Life Sciences, Lowell, MA) 
coated with 0.1% gelatin (Sigma, St. Louis, MO). All cell culture media and media 
supplements were purchased from Invitrogen (Carlsbad, CA) unless otherwise noted.  
For transient transfection in cell lines, cells (LMH) were plated in either 6-well or 24-
well culture plates (Corning Life Sciences) coated with 0.1% gelatin (Sigma) and allowed 
to grow overnight to a confluence of 90-95%. Typically, 3.5x10
5
 cells were used for 24-
well plates and 1.0x10
6
 cells were used for 6-well plates. The following day, cells were 
transfected using Lipofectamine-2000 transfection reagent (Invitrogen, Carlsbad, CA) 
according to the manufacturer’s protocol in OPTI-MEM for 6 hr, following which the 
medium was replaced with Waymouth’s medium with 0.01% BSA supplemented with 
penicillin and streptomycin. 
Cloning of untagged and tagged isoform constructs 
The primers used for cloning full-length Pit1 isoforms are listed in Table 1. All primers 
were obtained from Sigma-Aldrich (St. Louis, MO) unless mentioned otherwise. Chicken 
pituitary cDNA (e14) was amplified using Phusion Flash proof-reading polymerase 
(Finnzymes Inc., Woburn, MA), and the gel-extracted amplicon was digested with  
51 
 

































HindIII (Invitrogen, Carlsbad, CA) at 37°C for 4 hr in appropriate buffer. DNA from the 
restriction digestion reactions was purified and quantified by comparing to the intensity 
of the band(s) of the DNA ladder I (Genesee Scientific, San Diego, CA). Different 
insert:vector ratios (typically 1:1 and 3:1) were ligated non-directionally into pCMV-
Sport6.1 mammalian expression vector. Successful ligation was determined by diagnostic 
PCR using vector specific M13-forward and M13-reverse primers, and 2μl of the ligation 
reaction was transformed into DH5α Max Efficiency chemically competent cells 
(Invitrogen). Plasmid DNA was extracted using Nucleobond PC-500 Plasmid DNA 
purification kit (Macherey-Nagel, Bethlehem, PA) from ampicillin-resistant bacterial 
colonies grown overnight in the presence of 100μg/ml ampicillin, screened for 
directionality by PCR, and sequenced at the University of Maryland Center for 
Biosystems Research. Each clone was sequenced in two directions in its entirety to 
ensure absence of mutations.  
For generating N-terminally hemagglutinin (HA)- and c-myc-tagged clones, forward 
primers were designed to contain a Hind-III site, a Kozak sequence, and the HA or c-myc 
sequence in that order. A single primer amplified Pit1α and Pit1β1, while two other 
primers were designed for Pit1β2 and Pit1γ. The forward primers were used in 
conjunction with a common anti-sense primer. For C-terminal tagging, a similar approach 
was used, but only one antisense primer was designed which contained the tag, a stop 
codon and a HindIII site. These tagging primers were used with isoform specific forward 




For cloning cDNA encoding C-terminal 784 amino acids of chicken CREB-binding 
protein (cCBP), primers were designed to amplify cDNA corresponding to the 3’-2402bp 
of the cCBP (Genbank Accession no. XM_414964). Chicken pituitary cDNA was 
amplified using these primers. The product of PCR was purified and further amplified 
with a forward primer encoding a HindIII site and Kozak sequence and a reverse primer 
encoding region a c-myc tag, stop codon and a HindIII site. Product obtained from the 
second round of PCR was purified and ligated into pSport6.1 expression vector and 
transformed into XL10B maximum efficiency competent cells. Plasmid DNA was 
isolated from positive clones, and the insert sequenced in its entirety in two directions.   
5’RACE of Pit1isoforms 
Primers used for 5’-RACE are listed in Table 2. Total RNA was extracted from e11 
chicken pituitaries using the RNeasy mini kit (Qiagen, Valencia, CA) and quantified 
using Quant-iT Ribogreen RNA Quantitation Reagent (Invitrogen, Carlsbad, CA). Total 
RNA (1μg) was reverse transcribed with Superscript III Reverse Transcriptase 
(Invitrogen) in a 20μl reaction using the common reverse primer (GSP1) used for cloning 
Pit1 isoforms. A negative control containing no reverse transcriptase was performed 
alongside to ensure there was no genomic DNA contamination. Synthesized cDNA was 
purified with Wizard SV
®
 Gel and PCR Clean-Up System (Promega, Madison, WI). Half 
of the cDNA obtained was tailed with dCTP by Terminal Transferase (TdT) (New 
England Biolabs, Ipswich, MA), while the other half served as a control reaction without 
TdT. Five microliters of the tailed reaction was amplified with forward Abridged Anchor 
Primer (AAP) (Invitrogen) and GSP1 (reverse primer). The first round of PCR was  
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followed by a second round of PCR in which AAP was replaced with Abridged Universal 
Anchor Primer (AUAP) (Invitrogen), while two different reverse primers were used as 
antisense: GSP3, annealing to a sequence present in Pit1α only, and GSP4/5, annealing to 
Pit1β1, Pit1β2 and Pit1γ. Specific Taq-amplified bands obtained in these amplification 
reactions were gel-purified and cloned into pGEM-T Easy Vector (Promega) by T/A 
cloning. Ligation reactions were transformed into JM109 cells and screened with 
blue/white screening. Colonies picked were grown overnight in TB broth with ampicillin 
in 96-well plates. After about 16 hr of growth, 100μl of the culture were transferred to a 
96-well plate and centrifuged at 1000xg for 5 min at 4°C. The supernatant was discarded, 
and the cells were resuspended in 50μl deionized water. The plates were sealed and cells 
were lysed in a thermocycler at 95°C for 5 min. These crude bacterial lysates were used 
as template in PCR with SP6/T7 primers to determine which clones contained an insert. 
Plasmid DNA was extracted from clones containing insert by the alkaline lysis method 
(Sambrook et al.) and sequenced as above.  
Immunocytochemistry 
Cells (LMH) were plated at 1x10
5
 per chamber in Lab-Tek II 2-chamber slides (Nalge 
Nunc International, Naperville, IL) and allowed to reach ~90% confluency. Cells were 
transfected with 2μg Pit1 isoform expression vector with Lipofectamine-2000. Empty 
expression vector was used as negative control. The following day, cells were washed 
twice with ice-cold PBS. For each wash, media in slides were decanted; PBS was added, 
and slides were rocked for 10 min at room temperature. Following washing, cells were 
fixed with freshly prepared 4% formaldehyde solution pH 7.5 (Thermo Scientific, 
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Rockford, IL) for 20 min. Slides were washed two more times, and permeablized in PBS 
with 0.1% Tween-20 and 0.1% Triton-X 100 for 8 min at room temperature. Chambers 
were removed, and the slides were washed 2 more times with PBS. Blocking was done 
for 1 hr at room temperature in PBS with 5% normal goat serum (NGS) (Jackson 
Immunoresearch Laboratories, Inc., West Grove, PA). Cells were washed twice with PBS 
and incubated with PIT1 antiserum (1:1000 dilution) at 4°C overnight in PBS/ 2% NGS. 
Primary antibody was excluded from one additional chamber transfected with Pit1α as a 
control.  The next day, cells were washed first in PBS then in PBS/0.1% Tween-20, and 
incubated with Rhodamine-conjugated goat anti-rabbit IgG (Jackson Immunoresearch) 
diluted 1:50 in PBS/0.025% Tween-20 with 2.5% NGS for 1 hr at room temperature in 
the dark. Following secondary antibody incubation, cells were washed with PBS and 
incubated with 5ng/ml 4',6-diamidino-2-phenylindole (DAPI) (Thermo Scientific) for 10 
min in the dark. Cells were then washed thoroughly, mounted in fluorescent-dye 
compatible mounting medium Fluoromount-G (Southern Biotech, Birmingham, AL) and 
stored in the dark. Cells were examined with a Zeiss AxioObserver.Z1 inverted 
microscope, and images were acquired using the Zeiss Axiovision Re1 4.6 software with 
the Zeiss Axiocam HRC camera. 
Western blot 
To determine expression of untagged and tagged constructs of  Pit1 and C-terminal c-
myc tagged cCBP fragment (1677-2442), LMH cells were plated at 1x10
5 
per well in 6-
well plates overnight until the cells were ~90% confluent. Cells were transfected with 
4µg expression plasmid using Lipofectamine 2000 (Invitrogen) according to 
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manufacturer’s instructions. Cells were allowed to express the transfected gene for 24 
hours, and then cells were lysed in100µl per well of lysis buffer [20mM Tris-HCl (pH 
7.5), 150mM NaCl, 1mM EDTA, 1mM ethylene glycol tetraacetic acid (EGTA), 1% 
Triton X-100)] containing 1mM phenylmethylsulfonyl fluoride (PMSF) and HALT™ 
Protease and Phosphatase inhibitor cocktail (Thermo Scientific) by rocking on ice for 15 
min. Plates were scraped, and all contents were transferred to microfuge tubes and 
incubated on ice for 15 min with vortexing every 3-4 min. Lysed cells were then 
centrifuged at 14000xg for 15 min at 4°C. Supernatants were transferred to a fresh tube 
and stored at -80°C. For total protein extraction from whole pituitaries, pooled (3-4) 
pituitaries were homogenized with a Dounce homogenizer in 200μl lysis buffer and 
centrifuged as above. Protein samples were quantified with Coomassie Plus (Bradford) 
Protein Assay kit (Thermo Fisher Scientific, Inc., Rockford, IL). Desired amounts of 
protein samples were diluted with 50mM Tris-HCl, pH 7.2, and then further diluted in an 
equal volume of Laemmli Sample Buffer (LSB) (BioRad, Hercules, CA) with 5% β-
mercaptoethanol and resolved in 10% (for PIT1) or 15% (for cCBP) polyacrylamide gels 
containing 0.1% sodium dodecyl sulphate (SDS) in Tris-glycine buffer (25mM Tris, 
192mM glycine, 0.1% SDS). Electrophoresed proteins were transferred onto Immobilon-
P polyvinylidene fluoride (PVDF) membranes (Millipore, Billerica, MA) using a Trans-
Blot SD Semi Dry Electrophoretic Transfer Cell (Bio Rad), blocked with 5% non-fat dry 
milk in Tris-buffered saline (TBS) with 0.1% Tween-20 (TBS/T) for 2 hr at room 
temperature or overnight at 4°C. Primary antibody incubation duration and dilutions were 
according to manufacturer’s instructions. The PIT1 antiserum used in all experiments was 
raised in rabbit against bacterially expressed full length rat PIT1 and was a kind gift from 
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Dr. Simon J. Rhodes of Indiana University School of Medicine, Indianapolis, Indiana. 
For over-expressed proteins, the PIT1 antibody was used at a dilution of 1:1000 overnight 
in TBS/T with 1% non-fat dry milk and 1% normal goat serum (NGS) (Jackson 
Immunoresearch) at 4°C. For endogenous PIT1 from chicken pituitary cells, a 1:500 
dilution was used. Rabbit anti-HA antibody (#H6908, Sigma) and mouse monoclonal 
anti-c-myc antibody (#A00704, Genscript, Piscataway, NJ) were both used at 1:1000 
dilution in TBS/T with 1% non-fat dry milk and 1% NGS. The next day, membranes 
were washed thoroughly in TBS/T with 1% milk and incubated with horse-radish 
peroxidase (HRP) conjugated secondary antibody (1:5000) in TBS/T with 1% non-fat dry 
milk for 2 hr at room temperature at the manufacturer’s recommended dilution. After 
extensive washing, blots were developed using Lumi-Glo enhanced chemiluminescent 
detection reagent (Cell Signaling Technologies, Danvers, MA). If required, blots were 
stripped in buffer containing 62mM Tris-HCl (pH 6.7), 100mM β-mercaptoethanol and 
2% SDS at 50°C for 30 min with occasional rocking. Membranes were washed in large 
volumes of TBS/T. Blocking and subsequent steps were performed as mentioned 
previously. 
Proteasome inhibitor assay 
For proteasome inhibitor assay, LMH cells were plated at 1x10
6
 per well in 6-well plates 
and allowed to attach overnight. Cells were transfected with 4μg Pit1 isoform expression 
vector or empty vector and allowed to express the transfected gene for 24 hours, 
following which cells were treated with 20μM MG-132 (Cayman Chemical, Ann Arbor, 
MI) for 0, 1.5 hr or 6 hr. At the end of incubation, cells were washed with ice-cold PBS 
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and lysed in cell lysis buffer, and total protein was extracted and quantified as mentioned 
previously. Equal amounts of total protein from each treatment were separated by 12% 
SDS-PAGE, transferred to PVDF membrane and blotted with PIT1 antiserum (1:1000). 
HRP-conjugated goat anti-rabbit IgG (1:5000; KPL Inc., Gaithersburg, MD) incubation 
was for 2 hr at room temperature in TBS/T with 1% non-fat dry milk. Detection of 
immunoreactive bands was performed as mentioned previously. 
Analysis of promoter activity 
For analysis of promoter activity, LMH cells were used. Cells were plated at 3x10
5 
per 
well in 24-well plates in Waymouth’s medium with 10% FBS and penicillin/streptomycin 
and allowed to attach for 6 hr in plates coated with 0.1% gelatin.  Cells were then visually 
inspected to ensure proper attachment. Medium was replaced with Opti-MEM, and cells 
were transfected with Lipofectamine-2000 according to the manufacturer’s instructions. 
Typically, each well received 3 plasmids: Pit1 isoform expression vector (or empty 
vector), cGh promoter reporter vector pGL3-1727 (or empty reporter vector, pGL3-basic) 
and normalization vector. Empty reporter plasmid and normalization plasmids were 
purchased from Promega. cGh promoter reporter vector was a kind gift from Dr. F.C. 
Leung (University of Hong Kong). Cells were transfected in Opti-MEM for 6 hr, after 
which transfection medium was replaced with serum-free Waymouth’s medium 
supplemented with BSA and Penicillin/Streptomycin. Cells were allowed to express 
transfected genes for 24 hr, after which cells were washed once with PBS and lysed in 
100μl passive lysis buffer (Promega) with rocking for 15 min. Cell lysates were collected 
in a fresh microfuge tube and stored at -20°C until assay. Samples were assayed for 
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firefly luciferase (reporter) and renilla luciferase (normalization) activity using the Dual-
Luciferase Reporter Assay Kit (Promega) according to the manufacturer’s instructions. 
For each sample, the ratio of firefly over renilla was determined and reported as such. 
Data are presented as mean + SEM of at least three replicate experiments., and p <0.05 
was considered significant.  
Electrophoretic mobility shift assay (EMSA) 
5’-infra-red labeled EMSA probes for the proximal chicken PIT1 binding site were 
obtained from Integrated DNA Technologies (Coralville, IA) and are listed in Table 3. 
Equal amounts of 20μM sense and anti-sense probe dilutions were annealed in a 
thermocycler (95°C 5 min, followed by slow cooling in thermocycler) to obtain 10μM 
double-stranded DNA stock solutions. Probe stocks were diluted 1:200 in TE buffer to 
make working dilutions (50nM). Total protein (5μg) from LMH cells transfected with 
titrated amounts of individual Pit1 isoform expression vectors to yield equal protein 
expression were used for EMSA. Protein samples were incubated in the dark with either 
labeled PIT1 probe, labeled PIT1 scrambled probe, or a labeled PIT1 probe with 100-fold 
excess of unlabeled probe in binding buffer for 30 min at room temperature (RT). 
Binding reactions contained buffer (10mM Tris, 50mM NaCl, 1 mM DTT, pH 7.5), 50ng 
sheared salmon sperm DNA, 5mM MgCl2, 2.5mM DTT, 0.25% Tween 20 and 0.2% NP-
40. At the end of incubation, 2μl of 10x Orange G loading dye (LI-COR Biosciences, 
Lincoln, NE) was added to each reaction, and the entire binding reaction was loaded onto 
6% non-denaturing polyacrylamide gels pre-run for 30 min in the cold room. 


























scanned by Odyssey infra-red scanner (LI-COR) at intensity 4. For statistical analysis, 
background-subtracted average intensity of 3 replicate experiments was subjected to 
ANOVA after blocking for gel.  
Co-immunoprecipitation 
For co-immunoprecipitation to detect interaction between isoforms, LMH cells were 
plated at 1x10
6
 cells per well in 6-well plates. Cells were transfected with 4μg of N-
terminally HA- or c-myc tagged Pit1 isoform expression vectors using Lipofectamine 
2000 according to manufacturer’s instructions. Twenty four hours after transfection, cells 
were washed twice with ice cold PBS with 1mM MgCl2, 0.1mM CaCl2 and lysed in lysis 
buffer (10mM HEPES, 150mM NaCl, 1mM EGTA, 0.1mM MgCl2) supplemented with 
PMSF and HALT™ Protease and phosphatase inhibitor cocktail (Thermo Scientific, 
Rockford, IL). Cells were rocked in lysis buffer for 30 min on ice, scraped and 
centrifuged at 14000xg for 15 min. The supernatant was transferred to a fresh 1.5mL 
tube, and an aliquot was quantified using Coomassie Plus™ protein assay reagent. For 
each transfection, equal amounts of fresh whole cell lysate (typically 300μg) were 
immunoprecipitated using either 1.0μg mouse monoclonal anti-c-myc antibody 
(Genscript) or normal mouse IgG (Jackson Immunoresearch). Lysates were incubated in 
500μl total volume for 1 hr at 4ᵒC with end-over-end turning.  Protein A/G agarose beads 
(Cell Signaling Technologies Inc.) (20μl per tube) were added, and the entire reaction 
was incubated at 4ᵒC overnight with turning. The beads were then washed four times in 
lysis buffer (composition as before, but with no protease and phosphatase inhibitor). 
Briefly, tubes were centrifuged at 1000xg for 5 min at 4°C, and the supernatant was 
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carefully aspirated out. Fresh lysis buffer (1ml) was added to each tube, and tubes were 
rotated at 4ᵒC for 10 min. At the end of the last wash, beads were resuspended in 20μl 
LSB with β-mercaptoethanol, boiled, and resolved by SDS-PAGE (10% gels). PVDF 
membranes containing the electrophoresed proteins were blocked with 5% non-fat dry 
milk in TBS/T overnight at 4ᵒC. The following day, membranes were washed in TBS/T 
and incubated with primary antibody [1:1000 rabbit anti-HA (Sigma)] overnight at 4ᵒC. 
After washing extensively with 1% non-fat dry milk in TBS/T, membranes were 
incubated with 1:5000 dilution of HRP-conjugated goat anti-rabbit IgG (KPL). 
Immunoreactive bands were detected as mentioned previously. Membranes were then 
stripped, and re-probed with anti-PIT1 anti-serum (1:1000) as described previously. 
 
Co-immunoprecipitation for detecting interaction of isoforms with cCBP(C-terminal 
myc-tagged C-784 amino acids) was done essentially the same way, except that 15% gels 
were used for electrophoresis. Lysates from cells transfected with empty vector, Pit1 
isoforms, C-terminal cCBP or both Pit1 isoforms and C-terminal cCBP were 
immunoprecipitated using c-myc antibody, and membranes were blotted with anti PIT1 
antiserum.  
Detection of phosphorylated PIT1 
Chicken pituitaries (e11, 120 per replicate) were dissected out and dispersed as described 
previously. The cells obtained were plated as 2 wells per treatment in a 6-well plate and 
cultured for 24 hr in DMEM/F12 supplemented with BSA, Penicillin/Streptomycin and 
insulin. The following day, cells were treated for 0, 1.5 or 6 hr with 10
-7
M CORT. At the 
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end of CORT treatment, cells were washed twice with ice-cold PBS/Ca/Mg and lysed in 
250μl lysis buffer [20mM Tris-HCl (pH 7.5), 150mM NaCl, 1mM EDTA, 1mM EGTA, 
1% Triton X-100)] containing 1mM PMSF and HALT™ Protease and Phosphatase 
inhibitor cocktail (Thermo Scientific) per well for 15 min on ice with rocking. Lysates 
were collected and centrifuged at 14000xg for 20 min at 4°C. The supernatant was 
transferred to a fresh tube and protein yield was quantified as mentioned previously.  
 
For antibody-bead crosslinking, 70μl of Protein A/G agarose (Cell Signaling 
Technologies, Inc.) beads were washed twice in PBS and incubated in the presence of 
20μl PIT1 antiserum diluted in 910μl PBS for 4 hr at 4°C with end-over-end turning. At 
the end of incubation, beads were washed once with ice-cold PBS to wash off unbound 
antibody. The antibody-bead mixture was crosslinked with 20mM Dimethyl pimelimidate 
dihydrochloride (DMP; Sigma) in 0.2M triethanolamine (Sigma) pH 8.7 for 30 min at 
room temperature with rotation. Beads were centrifuged at 1000xg for 5 min, and the 
cross-linking was repeated with fresh triethanolamine/DMP solution. The reaction was 
quenched with 0.2M ethanolamine pH8.0 (Santa Cruz Biotechnology) for 1 hr at room 
temperature with rotation. After quenching, beads were aliquoted into 3 tubes.  
 
Typically, 200μg of total protein was immunoprecipitated in IP buffer (composition same 
as lysis buffer except with 0.1% Triton X-100) with either PIT1 antiserum (cross-linked 
to beads) or normal rabbit serum in 500μl total volume at 4°C overnight with rotation. 
The next day, immunoprecipitates were washed 4 times with IP buffer. For each wash, 
reactions were centrifuged at 1000xg for 5 min at 4°C, the supernatant was aspirated off, 
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and beads were rotated for 10 min at 4°C in fresh buffer. At the end of the final wash, 
20μl of LSB was added to the beads and incubated at 37°C in a water bath for 30 min. 
For input, 10μg (5%) protein was diluted in LSB and incubated the same as IP reactions. 
Immunoprecipitated samples were separated in 10% polyacrylamide gels with SDS. 
Electrophoresed proteins were transferred to PVDF membranes and blocked with TBS/T 
with 2% normal goat serum. Blots were probed with 1:500 dilution of rabbit anti-
phospho-threonine antibody (Cell Signaling Technology) in TBS/T with 1% normal goat 
serum overnight at 4ᵒC. HRP-conjugated goat anti-rabbit secondary antibody (1:5000) 
treatment was in TBS/T+1% normal goat serum for 2 hr at room temperature. 
Immunoblot detection was performed as before. Blots were stripped and blotted for PIT1 
as mentioned previously, except a 1:500 dilution of primary antibody was used.  
 
Statistical analysis 
For luciferase reporter assays, the ratio of firefly to renilla luciferase was subjected to 2-
way analysis of variance (ANOVA) using the MIXED procedure in the Statistical 
Analysis System (SAS; SAS Institute, Cary, NC). For determining significant differences 
between band intensities in EMSA, mean average intensities from 3 replicate experiments 
were subjected  to 1-way ANOVA after blocking for gel. For both analyses, differences 
in Least Squares Means (LSM) between treatments were determined by option PDIFF in 





Cloning of Pit1 isoform cDNAs into expression vectors: Identification of a novel isoform 
mRNA 
At the start of this project, three Pit1 isoform mRNAs had been identified in chickens 
(Van As et al., 2000). However, translation of these isoform mRNAs to stable and 
functional proteins had not been demonstrated. To demonstrate translation of chicken 
Pit1 mRNAs into full length proteins, the isoforms were cloned into expression vectors. 
Chicken Pit1 isoforms Pit1α and Pit1β were amplified from chicken pituitary cDNA 
(e14) using forward and reverse primers (Table 1), and the amplicons were cloned into 
the p-CMV-Sport6.1 mammalian expression vector. Reverse primer binding to the 84-bp 
β-specific exon was used to differentiate between Pit1α and Pit1β. A different forward 
primer was used, along with the common reverse primer, to amplify Pit1γ. Since the 
same primer pair amplified the Pit1α and Pit1β isoforms (Fig. 5), it is possible to predict 
Pit1α mRNA to be present in e14 chicken pituitaries at a level substantially higher than 
Pit1β1. In fact, out of a total of 215 colonies screened, only 2 were found to contain the 
Pit1β1 clones. Recombinant plasmid constructs for each isoform were sequenced in both 
directions to confirm sequence integrity. Sequence comparison of Pit1 isoform cDNAs 
amplified from Ross broiler strain cDNA revealed few points of difference when 
























Fig. 5. Pit1 gene structure. Exons are represented as boxes, and introns are represented as lines. Exons and 
introns not to scale. Line arrows denote forward and reverse primer for isoforms Pit1α and Pit1β. Filled 
arrow denotes forward primer for Pit1γ. Chevron denotes β-specific reverse primer used for identification 
of β-clones. β-specific exon is in yellow. Unique exon 1 of Pit1γ is in black. White represents region of 




Sequencing results also revealed the presence of an isoform that lacked the first 26bp of 
the β-specific exon (Fig. 6). We predict this is a yet unidentified and novel isoform. To 
confirm that this was not a cloning artifact, we sequenced several other chicken pituitary 
mRNA samples of different ages (e11, e17, d32) which also showed the presence of this 
isoform. Initiation of translation of this novel isoform from the same site as Pit1α and 
Pit1β1would result in a completely different protein product that would not have amino 
acid sequence related to the reported PIT1 isoforms, except at the very N-terminal region 
up to the middle of the β-specific exon. However, if this isoform used a different ATG 
codon, it is possible to yield a protein product with a POU-domain similar in sequence as 
the other isoforms. Scrutiny of the cDNA sequence revealed only one such downstream 
ATG codon in the +2 frame which, if used, and if the transcript had been alternatively 
spliced, would result in a novel isoform of 315 amino acids, making this isoform the 
shortest of all known chicken PIT1 isoforms. This isoform is thus predicted to result from 
a combination of using an alternative translation start site as well as alternative splicing. 
A comparison of the mRNA structure of the isoforms is shown in Fig. 7.  
Determination of transcription start site of the isoforms by 5’RACE. 
It has been reported by Van As et al., 2004 that the Pit1 gene is transcribed as a single 
mRNA which then undergoes alternative splicing to derive isoforms Pit1α and Pit1β1, 
while a different mRNA, derived by alternative transcription start site (TSS) usage, leads 
to the Pit1γ isoform. To determine the TSS of the novel Pit1β2 isoform, and also to 
confirm if the TSS for the other isoforms is the same in Ross broiler strains as the Hybro 













Fig. 6. Sequence alignment of Pit1β1 and Pit1β2. Pit1 gene structure is shown on top. Sequences were 
aligned using CLUSTALW. Dashed line in Pit1β2 denotes portion of β-specific exon not present in Pit1β2. 
Only relevant portion showing difference is represented. Exon 1 is in red. Green shading represents 








Fig. 7. Comparative structure of Pit1 isoforms. For each isoform, the gene is represented in the form of 
introns (lines) and exons (boxes) along with transcription start site (TSS), 5’-untranslated region and mode 
of splicing, if present. Coding sequence is shown for all isoforms as exons (boxes). White boxes represents 




total RNA was reverse transcribed with reverse primer annealing to a common sequence 
located at the 3’-end. After tailing, cDNAs were amplified with two sets of primers to 
separate out Pit1α from Pit1β1, Pit1β2 and Pit1γ. These two sets of reactions were 
cloned into pGEM vector and multiple clones obtained and sequenced. Any insert not 
aligning to chromosome 1 in BLAST was not pursued further. Correct inserts were 
aligned with the Pit1 gene in Ensembl and the TSS determined.  We found the TSS of the 
mRNA giving rise to Pit1α and Pit1β1 to be 78base pairs upstream of the site previously 
reported, while our findings for Pit1γ showed the TSS to be 8base upstream from the site 
previously reported (Fig. 8). No clones containing Pit1β2, the novel isoform we 
discovered, were found in this screen. We derived cDNA from total pituitary RNA by 
reverse transcription with a primer that annealed to an exon-exon junction found only in 
Pit1β2 (Primer 5’RACE_Diag_Beta2, table 3). This cDNA was tailed, amplified with 
AAP/PIT1beta2-rev and sequenced. We found Pit1β2 also to be processed from the same 
TSS as Pit1α and Pit1β1, and we predict this isoform arises as a result of an alternative 
translation start site usage, from an mRNA that has been alternatively spliced 
downstream of the new start site (Fig. 8).  
PIT1 isoform protein expression in LMH cells 
To determine whether or not all isoform mRNAs identified can be translated into 
proteins, recombinant plasmids expressing cPIT1 isoforms were transfected into LMH 
cells. While this report was under preparation, expression of PIT1α and PIT1γ in non-







Fig. 8. 5’Rapid Amplification of cDNA Ends (RACE) of Pit1 isoforms. (A) Alignment of 5’RACE  
products of Pit1α, Pit1β1 and Pit1β2 with genomic sequence.. (B) Alignment of 5’RACE product of Pit1γ 
and genomic sequence. Transcription start site predicted from our results is denoted with arrow.Yellow 





four isoforms by Western blot with rabbit PIT1 antiserum, as shown in Fig. 9. However, 
we found differences in the levels of expression between the isoforms in both HEK-293 
(Fig. 9A) and LMH (Fig. 9B) cells. There were robust expression levels for isoforms 
alpha and beta2, while isoforms beta1 and gamma showed reduced levels with equal 
amounts of plasmid DNA transfected. In fact, we failed to detect PIT1γ expression in 
HEK293 cells (Fig. 9A). To address the possibility that one or more isoforms were 
subjected to proteosomal degradation, we conducted a proteasome inhibitor assay. LMH 
cells transfected with PIT1 isoform expression plasmids were allowed to express the 
transfected gene for 24 hours, following which cells were treated with MG-132 (20μM) 
for 0, 1.5 and 6 hr. However, we found no difference in expression after 6 hr of 20μM 
MG-132 treatment (Fig. 10). It should be mentioned that we tried using longer incubation 
periods (12 hr, and 24 hr) in the presence of MG-132, but these led to massive cell death 
at the concentration used.  
Also, we detected multiple bands, especially for PIT1α and PIT1β1 using the PIT1 
antiserum. These can be shorter isoforms resulting from premature translation 
termination, alternative downstream translation initiation site usage, shorter cleavage 
products derived from a full-length precursor, or products of partial degradation. To 
determine whether these were shorter peptides arising from the use of downstream 
translation start sites or whether they were degradation products, we used N- and C-
terminally HA tagged isoform constructs. As seen in Fig. 11B & C, multiple bands were 
not detected when an N-terminally tagged construct was used, but present when the tags 












Fig. 9. PIT1 isoform protein expression in HEK-293 (A) and LMH (B) cells. For each cell type, PIT1 
isoform expression vector or empty vector (4μg) were transfected  using Lipofectamine-2000. Total protein 
























Fig. 10. Proteasome inhibitor assay. LMH cells were plated at 1x10
6
 per well in 6-well plates and 
transfected with 4μg Pit1 isoform expression vector or empty vector and allowed to express the transfected 
gene for 24hours, following which cells were treated with 20μM MG-132 for 0, 1.5 hr or 6 hr. Equal 
amount of total protein from each treatment was resolved by SDS-PAGE, and blotted with PIT1 antiserum. 















Fig. 11. Expression of N-terminal and C-terminal HA and c-myc tagged PIT1 isoforms in LMH cells. LMH 
cells were transfected with N-terminal HA- and c-myc tagged PIT1 isoform expression vectors. Total 
protein was isolated, separated by SDS-PAGE, and blotted with anti-PIT1 antiserum (A), rabbit anti-HA 




products resulting from the use of a downstream in-frame translational start site. We 
examined the sequences of the isoforms to look for such ATG codons with Open Reading 
Frame Finder (ORF Finder, www.ncbi.nlm.nih.gov/projects/gorf/) and found several 
present. However, the possibility that these bands represent degradation products cannot 
be ruled out.  
An interesting observation was that an N-terminal tag on PIT1γ was not detectable by 
antibody directed against the tag. As a comparision of Fig. 11A vs. Fig. 11B & C reveals, 
even though detectable amounts of the PIT1γ isoform are present when blotted with the 
PIT1 antiserum, blotting with either anti-HA or anti-c-myc antibody failed to detect N-
terminally tagged PIT1γ. This suggests that the N-terminally located tag is either cleaved 
off or the N-terminus of the PIT1γ isoform is folded such that the tag is masked. 
Detection of endogenous PIT1 in chicken embryonic pituitary cells 
Even though all reported Pit1 isoform mRNAs are detectable in chicken embryonic 
pituitary cells by quantitative real-time PCR (Ellestad et al., 2011), whether or not all 
yield functional proteins is not known. Unfortunately, no antibodies are available that 
detect only one isoform but not others, making it impossible to answer this question. 
Hence, we took an alternate approach and resolved LMH whole cell extracts transfected 
with single PIT1 isoform expression vectors alongside e17 whole pituitary extracts by 
SDS-PAGE. The results can be seen in Fig. 12. From the results, it is difficult to conclude 
which isoforms are expressed. Endogenous PIT1α, the isoform most readily detected is 
resolved at the same position of the gel as overexpressed PIT1α, and the isoform slightly 














Fig. 12. Endogenous PIT1 from embryonic day 11 chicken pituitary cells. Whole cell lysates from e11 
primary cells were electrophoresed on the same gel with lysates from LMH cells transfected with either 
empty vector or a single PIT1 isoform. Anti-PIT1 antiserum (1:500) was used for immunoblotting. (N.S. 




conclude whether the shorter bands represent isoforms β2 and γ or they are shorter 
products arising from downstream ATG codons. Some of the higher molecular weight 
bands possibly represent homo- and heterodimers between endogenous PIT1 isoforms. It 
is also possible that the endogenous expression level of one or more isoform is below the 
level of detection without overexpression. 
PIT1 isoform protein localization in LMH cells 
So far, only one study has looked at nuclear localization abilities of wild type and mutant 
human PIT1 (Kishimoto et al., 2002). A cluster of 6 basic residues in the POU domain of 
Oct-1 is known to determine nuclear localization. This cluster (RKRKRR) is conserved 
in all isoforms of PIT1 and is considered to be the putative nuclear localization signal 
(NLS). However, sub-cellular localization of none of the PIT1 isoforms had been 
demonstrated empirically in chicken at the time this experiment was planned and 
performed. Recently, Murase et al., 2011 reported the localization of PIT1α and PIT1γ to 
the nucleus in Cos-7 cells, and their data are in agreement with our results, which show 
localization of all the isoforms to the nucleus in LMH cells (Fig. 13).  
PIT1 isoform protein (C-terminal HA tagged) localization in chicken embryonic pituitary 
cells 
To determine the sub-cellular localization of PIT1 isoforms in chicken pituitary cells, 
plasmid constructs expressing epitope-tagged isoforms were used. Cells were transfected 
with C-terminal HA tagged PIT1 isoforms along with expression plasmid for golgi-







Fig. 13. Sub-cellular localization of PIT1 isoforms in LMH cells. Cells were plated in  2-chamber slides 
and transfected with 2μg Pit1 isoform expression vector. Cells were fixed, permeablized, incubated with 
PIT1 antiserum (1:1000 dilution) at 4ᵒC overnight in PBS/ 2% NGS. Following secondary antibody 
(Rhodamine-conjugated goat anti-rabbit IgG) incubation, cells were incubated with DAPI, mounted in 
Fluoromount-G and visualized with a Zeiss fluorescent microscope using Axiovision LE software version 




primary chicken pituitary cells, transfection was performed in suspension. High cell 
numbers, close to 2x10
6
 cells per chamber in 8-chambered slides were used to get high 
cell density. GFP expression was observed as punctuate green staining outside the 
nucleus. Cell nuclei were stained with DAPI. Localization of tagged PIT1 isoforms in 
e19 chicken pituitary cells was also predominantly in the nucleus (Fig. 14). We also 
examined if CORT had an effect on the localization. Transfected cells were treated with 
CORT (10
-7
M) 24 hr after transfection, but CORT had no effect on localization of the 
isoforms in chicken embryonic pituitary cells (data not shown). It should be noted that 
even though almost all PIT1 expression in both chicken pituitary cells and when over-
expressed in LMH cells was nuclear, isoform proteins were readily detectable in whole 
cell lysate.   
Activation of the chicken Gh promoter by PIT1 isoforms in LMH cells 
To determine which, if any, of the PIT1 isoforms can activate the chicken Gh promoter, 
we performed a dual-luciferase reporter assay with a pGL3-1727 reporter vector in which 
the firefly luciferase gene is driven by -1727 to +48bp of the cGh promoter. This region 
of 1774bp of the cGh 5’flanking region has been shown to be sufficient for mediating 
glucocorticoid activation of cGh gene expression both in rat pituitary GH4C1 cells by 
dexamethasone (Ip et al., 2004) and chicken pituitary primary cells by CORT (Knubel, 
2010). However, for our purposes it was essential to perform the experiments in a 
situation where only one isoform of PIT1 would be present. We could not use a rat or 
mouse pituitary cell line as the cGh reporter has been shown to be activated in 






Fig. 14. Sub-cellular localization of PIT1 isoforms in chicken pituitary cells. Cells were plated in 8-
chamber slides and transfected with 2μg C-terminal HA-tagged Pit1 isoform expression vector. Cells were 
fixed, permeablized incubated with anti-HA antibody (1:1000 dilution) at 4ᵒC overnight in PBS/ 2% NGS. 
Following secondary antibody (Rhodamine-conjugated goat anti-rabbit IgG) incubation, cells were 
incubated with DAPI, mounted in Fluoromount-G and visualized with Zeiss fluorescent microscope using 






per well in 24-well plates) on gelatin-coated plates. Cells were 
transfected with 1μg of either empty reporter vector backbone (pGL3-Basic) or the cGh 
reporter vector (pGL3-1727) along with specified amounts of Pit1 isoform expression 
vector and 20ng pRL-SV40 renilla luciferase normalization vector. The amount of 
expression vector transfected was kept constant (2μg) with empty expression vector 
(pCMV-Sport6.1). Initially, a dose-response study was conducted with 1ng, 10ng, 100ng 
and 1000ng of expression vector. Ratios obtained by dividing the firefly luciferase 
activity by renilla luciferase activity are shown in Fig. 15. Different letters denote 
significant differences of Least Squared Means between treatment groups (n=4, p<0.05). 
The isoforms PIT1α, PIT1β1 and Pit-β2 showed a dose-dependent activation of the cGh 
promoter, while PIT1γ did not activate the promoter even at the highest dose. The three 
activating isoforms showed lower activation at a dose of 100ng. However, no significant 
activation was seen at 10ng or below. In a pilot study, similar luciferase reporter assays 
(using 1000ng expression vector) were conducted in presence and absence of 10
-7
M 
CORT for 24 hr. We saw no difference in the activation of cGh promoter in presence of 
CORT, regardless of which PIT1 isoform was tested (data not shown).  
 
Since we had previously detected differences in the level of isoform protein expression 
from recombinant plasmid in LMH cells, we transfected additional wells with identical 
amounts of reporter, expression and normalization vectors and extracted total protein at 
the same time the other wells were lysed to obtain samples for reporter assays. Samples 
were resolved by SDS-PAGE and blotted with PIT1 antibody. As seen previously, 

























 Fig. 15. Activation of the chicken Gh promoter by PIT1 isoforms in LMH cells. Figure shows dose-
dependent activation of the cGh promoter by PIT1 isoforms. For each dose, specified amount of expression 
plasmid was transfected along with either 1μg pGL3-Basic or pGL3-1727 along with 20ng pSV-40 renilla.  
Different letters denote significant differences of Least Squared Means between treatment groups Data 




widely among the isoforms (Fig. 16). Blots were stripped and reprobed with mouse anti-
α-tubulin antibody (1:1000; sc-32293; Santa Cruz Biotechnology, Santa Cruz, CA) which 
confirmed that equivalent amounts of total protein were loaded.   
 
Since a difference in level of expression of PIT1 proteins was apparent, we titrated the 
amount of DNA transfected to obtain equal levels of PIT1 protein expression (Fig. 17). 
For each isoform, a lower and a higher dose was selected and protein expression 
determined by Western blot (Fig. 17B). The amounts of plasmids obtained from titrations 
that yielded equivalent amounts of PIT1 protein, were transfected into LMH cells and the 
promoter activity measured the same way as before. The total amount of plasmid DNA 
transfected was kept constant with empty pCMV-Sport6.1 vector. Once again, PIT1γ 
failed to activate the cGh promoter, even when the amount of PIT1 protein present was 
comparable to the other isoforms (Fig. 17A). A significant effect was seen when 
PIT1γ(3000ng)/pGL3-1727 is compared to pSport6.1/pGL3-1727, but we believe this 
result is due to an effect that the large amount of transfected PIT1γ has on renilla 
luciferase, as we saw a significant decrease of renilla activity at this dose. PIT1β1 gave 
the maximum activation of approximately 15-fold over empty expression vector. The 
amounts of PIT1α transfected were 10ng and 50ng, and neither of these doses activated 
the cGh promoter similar to the result seen in the dose-response experiment. Only the 
higher dose of PIT1β2 activated the cGh promoter. Taken together, these results indicate 
that all known isoforms of PIT1 except PIT1γ can activate the cGh promoter in non-




Fig. 16. Protein expression of PIT1 isoforms transfected with 1ng, 10ng, 100ng and 1000ng Pit1 
expression vector. PIT1 antiserum (1:1000) was used for immunoblotting. Blots were then stripped and 










Fig. 17. Activation of the chicken Gh promoter by PIT1 isoforms in LMH cells. (A) shows activation of the 
cGh promoter by PIT1 isoforms when comparable amount of protein is expressed. The amount of PIT1 
isoform expressed was determined by Western blot (B). Alpha tubulin was used as a loading control. For 
each dose, specified amount of expression plasmid was transfected along with either 1μg pGL3-Basic or 
pGL3-1727 along with 20ng pSV-40 renilla. Asterisk denotes significant difference from cells transfected 
with empty expression vector. Dagger (†) denotes significant difference from cells transfected with 




Isoform protein binding to the proximal PIT1 binding site on the cGh promoter 
Since we detected no activation of the cGh promoter by PIT1γ, we hypothesized that this 
inactivity may be due to the fact that PIT1γ cannot bind to the proximal PIT1 binding 
site. There are two putative PIT1 binding sites within 1kb of the cGh promoter. The 
proximal site is located at -104/-113 bp, and the distal site is located further upstream at -
533/-541bp. Of the two PIT1 binding sites present, we decided to test for binding of the 
isoforms to the proximal site, because that is the site which is known to be functionally 
important (Ip et al., 2004). Mutations in either both or only the proximal site abolish 
promoter activation in rat pituitary GH4C1 cells. Also, GH4C1 cell extracts bound only 
to the proximal site in vitro. DNA probes were designed spanning the proximal PIT1 
binding site and incubated with total protein lysates of LMH cells transfected with single 
Pit1 isoform expression vectors. The amount of expression vector transfected varied 
according to isoform to obtain comparable PIT1 protein expression levels. In our 
experiments, we found specific significant binding of all isoforms except PIT1γ to the 
proximal PIT1 binding site (Fig. 18A). The binding showed by PIT1γ was less than 
others that was not statistically significant. This binding was successfully competed off 
using a 100-fold molar excess of unlabeled probe. A labeled mutant probe, with the 
proximal PIT1 binding sequence and neighboring bases mutated to a GC-rich sequence as 
opposed to the AT-rich sequence recognized by PIT1, showed no specific binding. The 
same mutation has been shown to result in no binding by rat PIT1 to the proximal site of 
the cGh promoter (Ip et al., 2004). Whole cell extract from cells transfected with empty 
expression vector showed some binding which was not competed off with excess 




















Fig. 18. Isoform protein binding to the proximal PIT1 binding site on the cGh promoter. (A)EMSA 
showing PIT1 isoform protein binding to the proximal PIT1 binding site on the cGh promoter (Top: Pit1-α 
and PIT1β1; Bottom: PIT1β2 and PIT1γ). Infra-red labelled DNA probes were designed spanning the 
proximal PIT1 binding site and incubated with total protein lysates of LMH cells transfected with single 
PIT1 isoforms expression vectors.  DNA-Protein complexes were resolved in 6% non-denaturing 
polyacrylamide gels. Boxes denote specific bands for each PIT1 isoforms. (B) Quantitation of PIT1 
isoform binding to cGh promoter. Means of background-subtracted average intensity of 3 replicate 
experiments were subjected to ANOVA after blocking for gel (p<0.05). The amount of expression vector 
transfected varied according to isoform to obtain comparable protein expression levels. (C) Western blot 
showing level of protein expression obtained with specifed amount of plasmid DNA transfected in samples 








times, and average binding for each isoform was quantified and compared with binding 
by pSport6.1-transfected LMH cell extract (Fig. 18B).  Since comparable amounts of all 
the isoform proteins were present in the cell lysates (Fig. 18C), we conclude that PIT1γ, 
in spite of possessing the POU-homeodomain and POU-specific domain identical to the 
other isoforms, lacks the ability to bind to the proximal PIT1 binding site of the cGh 
promoter. 
Effect of co-transfection of an isoform on the activity of another 
Expression of multiple protein products from a single gene by alternative transcription, 
translation and/or splicing is a mode of expansion of the genome. However, one would 
expect a functional aspect to this. Based on what our results showed so far, we found that 
isoforms PIT1α, PIT1β1 and PIT1β2 can activate the cGh promoter, while PIT1γ cannot. 
Among those isoforms that had an activating role, PIT1β1 seems to activate the promoter 
to a higher level when the amount of isoform protein present is equal for all isoforms. 
Arbitrarily classifying the isoforms as most activating (PIT1β1), activating (PIT1α and 
PIT1β2) and not activating (PIT1γ), we intended to see what effect the isoforms might 
have on the activity of each other.  
There are very few studies done looking at the effect of co-transfection of PIT1 isoforms 
on promoter activation. In sheep, two isoforms PIT1γ and PIT1δ, which lack exon 3 and 
exons 3, 4 and 5, respectively, act as dominant negative inhibitors of PIT1wt in 
regulation of the rat Prl promoter in HeLa cells (Bastos et al., 2006). Based on our results 
showing inability of PIT1γ to activate the cGh promoter, PIT1γ was hypothesized instead 
to have a negative and/or regulatory role. There are two possible mechanisms by which 
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that could be employed: i) PIT1γ occupies the PIT1 binding site, thus preventing 
activating isoforms from binding and ii) PIT1γ heterodimerizes with activating isoforms, 
thus preventing them from binding to the promoter. Our EMSA results showed that 
PIT1γ does not bind the cGh promoter, thus eliminating the first possibility. To test if 
PIT1γ sequesters an activating isoform, we co-transfected PIT1β1 and PIT1γ in LMH 
cells and evaluated cGh promoter activation. The amount of expression vector transfected 
for each isoform was such that they yielded comparable protein expression, and also the 
co-transfection had as much DNA transfected as the individual transfections.  As seen in 
Fig. 19A, the presence of PIT1γ did not affect the ability of PIT1β1 to activate the cGh 
promoter. The level of activation achieved by PIT1β1 in the presence of PIT1γ was 
comparable to that by PIT1β1 alone (n=3, p<0.05). Thus, PIT1γ does not negatively 
regulate activation of the cGh promoter by PIT1β1 in LMH cells. 
As mentioned previously, both PIT1α and PIT1β2 activate the cGh promoter. However, 
the level of activation achieved by these two isoforms is less than that of PIT1β1 if 
comparisons are made when comparable amounts of isoform protein are expressed. We 
asked the question if expressing them together leads to an additive or synergistic 
activation of the promoter. The amount of plasmid DNA transfected was determined 
from the results of titration experiments (Fig. 17A & B) to yield equal protein expression. 
As seen in the results presented in Fig. 19B, co-expressing PIT1α and PIT1β2 did not 
have an additive effect on cGh promoter activation. Another combination of activating 
isoforms, PIT1β1 and PIT1β2, was tested. In this experiment, like the others, amounts of 
plasmid DNA transfected were such that the doses activated the cGh promoter as well as 













Fig.19. Effect of co-transfection of an isoform on the activity of another. Two isoforms at a time were co-
transfected in LMH cells and cGh promoter activation was evaluated. The combinations tested were (A) 
PIT1β1 and PIT1γ; (B) PIT1α and PIT1β2; (C) PIT1β1 and PIT1β2; and (D) PIT1α and PIT1β2. The 
amount of expression vector transfected for each isoform was such that they yielded comparable protein 
expression, and also the co-transfection had as much DNA transfected as the individual transfections. For 
each dose, specified amount of expression plasmid was transfected along with either 1μg pGL3-Basic or 







show an additive and possibly synergistic activation of the cGh promoter in the presence 
of both isoforms. The level of activation achieved by either 1000ng of Pit1β1 or 1000ng 
of Pit1β2 is significantly less than that obtained when 400ng of Pit1β2 and 600ng of 
Pit1β1 are simultaneously transfected (p<0.05, n=3). A fourth possible combination was 
tested in which Pit1β1 was transfected along with Pit1α (Fig. 19D). With this 
combination, significantly higher activation of the promoter was obtained with 600ng 
Pit1β1 transfected with 400ng Pit1α than with 1000ng of either isoform transfected alone 
(p<0.05, n=3). Taken together, these results suggest that PIT1β1, if expressed along with 
either PIT1α or PIT1β2, leads to an increased activation of the cGh promoter than either 
isoform expressed alone. In contrast, co-expression of PIT1α and PIT1β2, showed no 
additive or synergistic activation of the cGh promoter.  
Physical interaction between PIT1 isoforms co-expressed in LMH cells 
Even though PIT1 exists predominantly as a monomer in solution, it has been suggested 
that PIT1 binds DNA as a dimer, either as a homodimer or a heterodimer. Encouraged by 
our results showing increased activation of the cGh promoter by isoform combinations 
over isoforms expressed alone, we sought to determine if this was brought about by 
physical protein-protein interactions between the isoforms. LMH cells were transfected 
with expression vectors encoding N-terminal c-myc tagged PIT1β1 alone and in 
combination with N-terminal HA-tagged PIT1α or PIT1β2. Cells transfected with empty 
expression vector, HA-tagged Pit1α and HA-tagged Pit1β2 were also included in the 
experiment. Fresh lysates from each transfection were divided into two parts and 
immunoprecipitated with either mouse anti-c-myc antibody or normal mouse serum 
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(NMS). Immunoprecipitated samples were resolved by SDS-PAGE, blotted onto PVDF 
membrane and probed with rabbit anti-HA antibody. We performed this experiment in 
the presence and absence of DNA containing the PIT1 binding site(s). Employing this 
strategy, we were not able to demonstrate any protein-protein interaction between the 
isoforms by co-immunoprecipitation (Fig. 20). While individual isoforms were 
immunoprecipitated by antibodies directed against the tag, the potential dimerization 
partners were not co-immunoprecipitated.  We have also performed this experiment in rat 
pituitary GH4C1 cells, with the same result. However, in the absence of a positive 
control, we cannot conclude if the isoforms do not interact or if the interaction is transient 
and does not withstand the manipulation of protein extraction and immunoprecipitation.  
Physical interaction between PIT1 isoforms and chicken CREB-binding protein (cCBP) 
cAMP-mediated gene regulation can be either CREB-dependent or CREB-independent, 
and regulation of Gh in humans, despite the presence of functional CREs on the hGh 
promoter, appears to belong to the latter category (Cohen et al., 1999). The mechanism of 
CREB-independent activation postulated involves interaction of CREB-binding protein 
(CBP) with a gene-specific transcription factor bound to the promoter. CBP, by its 
intrinsic histone acetyltransferase (HAT) activity, remodels the local chromatin and also 
interacts with the general transcriptional machinery. Both rat and chicken Gh promoters 
lack a classical CRE core motif, but cAMP is involved in regulation of Gh in both 
species, and in rats the cAMP response is no longer present if the PIT1 binding sites are 








Fig. 20. Assays for physical interaction between co-transfected isoforms. LMH cells were transfected with 
N-terminal c-myc tagged Pit-α alone and in combination with N-terminal HA-tagged PIT1β2. Cells 
transfected with empty expression vector, and HA-tagged PIT1β1 were also included in the experiment. 
Fresh lysates from each transfection were divided into two parts and immunoprecipitated with either mouse 
anti-c-myc antibody or normal mouse serum (NMS). Immunoprecipitated samples were resolved by SDS-
PAGE, blotted into PVDF membrane and probed with rabbit anti-HA antibody. Large arrow indicates the 
location of where PIT1α and PIT1β1 should be located. Blot on extreme left shows 5% input blotted with 





involving an interaction of PIT1 with CBP, a known interaction partner of several other 
transcriptional regulators and a target of phosphorylation by protein kinase A (PKA) and 
protein kinase C (PKC). We hypothesized that PIT1 regulation of cGh will involve 
interaction of PIT1 with CBP, and that the most activating isoform (PIT1β1) will show a 
higher level of interaction than either PIT1α or PIT1β2. The region of CBP essential for 
regulating Gh has been shown to be located at the C-terminus and contain a functionally 
active Histidine rich domain (C/H3). We cloned this domain of the chicken CBP into 
pCMV-Sport6.1 mammalian expression vector with a C-terminal c-myc tag. The 
translation product obtained from this vector should lack the CREB-binding domain of 
CBP, and any interaction seen in the presence of cGh promoter DNA, then, must be 
mediated by PIT1. We transfected LMH cells with c-myc-cCBP (1677-2442), and a band 
of the correct size (90KDa) was detected using anti-c-myc antibody (data not shown). For 
co-immunoprecipitation, LMH cells were transfected with empty vector, PIT1, cCBP 
(1677-2442), and PIT1/cCBP(1677-2442) with pGL3-1727 reporter vector. Lysates were 
immunoprecipitated with anti-c-myc antibody, run onto SDS-PAGE gel and blotted with 
anti-PIT1 antibody. Despite several attempts, we were not able to demonstrate interaction 
between PIT1 isoform(s) and cCBP (data not shown). 
Detection of phosphorylation of PIT1 
Phosphorylation of PIT1 appears to modulate its ability to bind cognate sequences in 
promoter regions of target genes. There is evidence of PIT1 phosphorylation in regulation 
of Prl and TSHβ expression (Steinfelder et al., 1992; Howard & Maurer, 1994). 
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However, there are conflicting reports about the requirement of PIT1 phosphorylation in 
Prl gene regulation.  
Unpublished results from our lab (Malkiewicz, 2003; Ellestad, 2010) have shown the 
involvement of p38 MAPK and MEK1/2 pathways in glucocorticoid (GC) induction of 
somatotroph differentiation and Gh gene expression. PIT1 is a known target of Ras, PKA 
and PKC pathways in mammals. Based on these results, we predicted an involvement of 
these signaling pathways in CORT-induced Gh expression. We hypothesize that the GC 
activates PIT1 protein by phosphorylation at a threonine residue, conserved in all chicken 
PIT1 isoforms (Thr263 in PIT1α; Thr291 in PIT1β; Thr242 in PIT1β2 and Thr255 in 
PIT1γ), as well as in PIT1 found in other mammalian species and in the related 
transcription factor Oct-1. To test this hypothesis, we sought to determine if CORT 
induces phosphorylation of PIT1. Chicken pituitary cells (e11, 1x10
7
 per treatment) were 
cultured in the presence of CORT (10
-7
M) for 0 (basal), 1.5 and 6 hr. These time points 
were chosen as previous results from our laboratory have shown that activation of 
signaling pathways and Gh expression begins at 1.5 hr and continues up to 6 hr. Total 
protein extracted from these cells was immunoprecipitated using anti-PIT1 anti-serum or 
normal rabbit serum. Immunoprecipitated proteins were washed and resolved by SDS-
PAGE. Proteins were transferred onto PVDF membrane and probed with rabbit 
polyclonal anti-P-Thr antibody. Membranes were stripped and probed with anti PIT1 
antiserum to show the presence of immunoprecipitated PIT1. This experiment was 
replicated 4 times, and even though we could detect phosphorylated PIT1 in one 











Fig. 21. Assay for phosphorylation of PIT1 in response to corticosterone (CORT). Pituitary cells (e 11) 
cells were plated (1x10
7 
per well) in 6-well plates and treated with CORT (10
-7
 M) for 0, 1.5 or 6 hr. Total 
protein extracted from these cells was immunoprecipitated using anti-PIT1 anti-serum or normal rabbit 
serum. Immunoprecipitated proteins were washed and resolved by SDS-PAGE. Proteins were transferred 
onto PVDF membrane and probed with rabbit polyclonal anti-P-Thr antibody. Membranes were stripped 
and probed with anti PIT1 antiserum to show the presence of immunoprecipitated PIT1. This experiment 






The overall objective of this study was to characterize chicken Pituitary Specific 
Transcription Factor I (cPIT1) isoforms for their ability to regulate cGh gene expression. 
PIT1 has been shown to be essential for differentiation of somatotrophs and other anterior 
pituitary cells of the PIT1 lineage, as well as for spatial and temporal regulation of Gh 
gene expression. Multiple PIT1 isoform proteins are known to co-exist in anterior 
pituitary somatotrophs, lactotrophs and thyrotrophs, but the significance of having 
multiple isoforms is not known.  
 
The presence of three Pit1 isoform mRNAs in chicken was reported by Van As, et al. 
(2000). At the time this project was started, verification of chicken PIT1 isoform protein 
expression and functional characterization had not been done. Recently, Murase, et al. 
(2011) reported cloning and partial characterization of two PIT1 isoforms, PIT1α and 
PIT1γ for their ability to transactivate the cGh gene. However, our work is the first to 
report expression, functional characterization and investigation of the mechanism leading 
to differences in activation potential of the cGh promoter for all the known isoforms. We 
hypothesized that PIT1γ, due to a grossly different N-terminal transactivation domain 
completely lacking exon 1, will not transactivate the cGh promoter.  
 
The results reported here, with two exceptions, are from experiments performed in a non-
pituitary chicken cell line. Since multiple isoforms of PIT1 are present in cells of the 
PIT1 lineage, it was imperative to perform the experiments in cells that do not express 
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PIT1 endogenously. Gonadotrophs and corticotrophs are known to express Pit1 mRNA, 
which is suppressed at the level of translation (Simmons et al., 1990; Asa et al., 1996), 
thus making them unsuitable for our studies. Use of a chicken cell line was necessary, as 
initial trial experiments in a human cell line (HEK-293) showed suppression of protein 
expression of one of the isoforms (PIT1γ). A luciferase reporter gene driven by 1774bp 
of the cGh promoter was used to evaluate transactivation properties of the cPIT1 
isoforms. This reporter construct gave specific dose-dependent activation of the cGh 
promoter in the presence of over-expressed PIT1. Thus, we conclude this to be an 
appropriate system for our studies.  
 
In our attempt to clone full-length isoform cDNAs into an expression vector, we 
identified a novel isoform (PIT1β2) that lacks 26bp at the 5’-end of the β-specific 84bp 
exon present in PIT1β1 and PIT1γ. We predict that this isoform is translated from an 
initiation codon located in exon 1 downstream of the start site used by Pit1α and Pit1β1 
from an mRNA that is alternatively spliced (Fig. 7). This isoform, which we named 
Pit1β2, differs from the other known isoforms in the N-terminal transactivation domain, 
while the C-terminal POU-domain is conserved, and PIT1β2 is the shortest of all PIT1 
isoforms, comprising 315 amino acids.  
 
5’RACE was performed to identify the TSS of the isoforms.  PIT1 isoforms α, β1 and β2 
were found to have a common TSS. Thus, these three isoforms were transcribed as a 
single mRNA, which was then alternatively spliced and translated from alternate Met 
codons to give rise to the isoforms mentioned. However, our results indicate this TSS to 
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be located 128bp upstream of the translation start site. The TSS of the avian-specific 
isoform Pit1γ is different, and our findings for the TSS of Pit1γ show the initiation of 
transcription within introns 1, 90bp upstream of translation start site.  
 
Protein expression of chicken PIT1 isoforms from recombinant plasmid revealed certain 
interesting points. PIT1γ protein was either not expressed or very unstable in non-chicken 
cell lines. Even when detectable in a chicken cell line, the level of expression was lower 
than other isoforms when the same amount of plasmid was transfected. Based on our 
results, it does not appear likely that this isoform is subjected to proteosomal degradation, 
and the impaired translation is not due to an imperfect Kozak sequence, because 
expression was also lower than the other isoforms when the endogenous sequence was 
replaced by a perfect Kozak sequence. A possible mechanism behind such regulated 
expression might be phosphorylation of PIT1γ, a modification that unmasks a hidden 
degradation signal. However, in absence of isoforom specific antibody this could not be 
tested empirically. Also, post-translational modifications of this isoform appear to be 
different than the others, as demonstrated by either masking or cleavage of an epitope tag 
placed at the N-terminal end of the protein. It should be mentioned that the level of 
expression of PIT1β1 was also lower than that observed for PIT1α and PIT1β2 in our 
transient transfection experiments. 
 
A consistent feature of over-expression of PIT1 isoforms in LMH cells was the presence 
of multiple bands detected when blotted with the PIT1 antiserum. The identities of these 
peptides are not known. The presence of multiple in-frame start codons in the PIT1 
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protein sequence gives rise to the possibility that these are stable, shorter peptides which 
differ from each other in their N-terminus. While the possibility that these are products of 
proteolytic degradation exists, results from Western blots for N- and C-terminally 
epitope-tagged proteins strongly indicate otherwise. As shown in Fig. 11, we detected 
single bands when N-terminally tagged isoforms were probed with antibody against the 
tag, but multiple bands were detected when the same lysates were probed with the PIT1 
antiserum. Multiple bands were also detected when the tag was placed at the C-terminus. 
If an endopeptidase was involved, we would expect to see multiple bands with N-
terminally tagged constructs with antibody directed against the tag. We detected these 
shorter products in both fresh and freeze-thawed lysates, thus suggesting these are not 
degradation products arising after denaturation of protease inhibitors used in protein 
extraction. Protein sequencing (N-terminal sequencing) might be used as a tool to 
determine the identity of these bands. 
 
The functional significance of these shorter proteins is not known. In mammals, a 
functional isoform arises from using a downstream in-frame Met codon that activates the 
Prl promoter just like PIT1, while it has no effect on Gh promoter activation (Voss et al., 
1991). Future studies are warranted to find out whether these shorter proteins in chicken 
are functional and can be designated as novel isoforms. However, we are not certain if 
these shorter isoforms are stable in pituitary somatotrophs. 
 
Luciferase reporter assays with a construct containing -1727/+48 of the cGh promoter 
driving expression of a reporter gene showed that cells expressing any PIT1 isoform 
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activated the cGh promoter significantly over cells  expressing no PIT1. The response 
was found to be specific and dose-dependent. For the highest dose transfected, the 
isoforms PIT1α, PIT1β1 and PIT1β2 gave a 10-fold activation of the cGh promoter over 
cells expressing empty vector, while for PIT1γ the activation was about 3-fold. These 
results are in agreement with comparable work done with PIT1α and PIT1γ by Murase et 
al. (2011) in CHO-K1 cells. However, even though the activation caused by PIT1γ is 
statistically significant compared to that caused by empty expression vector, it is not 
significant when compared with that achieved with an empty reporter vector. This may 
indicate that the activation is non-specific and thus, we should exercise caution in 
interpreting it. At a lower dose of 100ng, PIT1γ lost its ability to transactivate the cGh 
promoter, while the other isoforms still exhibited more than 5-fold activation of the 
promoter.  
 
Due to the lower abundance of PIT1γ protein in transfected cells, we wanted to ensure 
expression of comparable levels of proteins when promoter activities were tested. In such 
titration experiments, we had to transfect very low amounts of PIT1α and PIT1β2 to 
obtain protein expression comparable to that obtained with much more Pit1β1 and Pit1γ 
expression vectors. At such doses, PIT1γ (3000ng) resulted in a 3-fold activation of the 
promoter, but this was not significantly different than when an empty reporter vector was 
used. We compared these two results, because expressing 3000ng of PIT1γ had resulted 
in a suppression of the renilla luciferase. Similar suppression was not seen with the doses 
of other isoforms transfected. When comparable protein expression was obtained, PIT1β2 
resulted in a 20-fold activation of the promoter, significantly higher than those by PIT1α 
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and PIT1β2, while the last two were not significantly different from each other. Overall, 
our results indicate that PIT1γ is not as capable of transactivating the cGh promoter as the 
other isoforms. This is actually what we hypothesized based on the fact that the structure 
of the N-terminal transactivation domain of PIT1γ is markedly different from the other 
isoforms. A limited activation is possible because even though the N-terminal domain is 
primarily involved in transactivation of target genes, some residual transcriptional 
activation is also associated with the POUHD (Theill et al., 1989; Ingraham et al., 1990). 
However, in our experiments, activation of the cGh promoter by PIT1γ was comparable 
to the effect of PIT1γ on an empty reporter construct. Thus, the activity of PIT1γ, if any, 
on the Gh promoter is questionable.  
 
All the isoform proteins were found to localize to the nucleus in both LMH and 
embryonic chicken pituitary cells. Localization of PIT1 to the nucleus has been shown in 
turkey (Weatherly et al., 2001), and recently, Murase et al. (2011) demonstrated nuclear 
localization of PIT1α and PIT1γ in Cos-7 cells. We demonstrated nuclear localization of 
all known chicken PIT1 isoforms to the nucleus of LMH cells and chicken embryonic 
pituitary cells. Thus, inability to localize to the nucleus is not responsible for the lack of 
activation of cGh promoter by PIT1γ. 
 
The current model of PIT1 regulated gene transcription involves PIT1 binding, via the 
POU-domain, to AT-rich sequences in the target gene promoter, followed by recruitment 
of other factors to facilitate transcription. Therefore, we decided to test if all PIT1 
isoforms bind to the functional, proximal PIT1 binding site to determine if reduced 
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activation by PIT1γ is due to lack of binding to the cGh promoter. The proximal PIT1 
binding site (ATCTGCAT) (Ohkubo et al., 1996) located at -104/-113 of the cGh 
promoter is the functional site (Ip et al., 2004, Murase et al., 2011). Previous results from 
our laboratory have shown that PIT1 binds the proximal site with increased affinity after 
1.5 hr of CORT treatment (i.e., before the initiation of Gh gene expression) and this 
decreases at 6 hr (Narayana and Porter, unpublished). However, these experiments were 
done with endogenous PIT1 in chicken pituitary cells, and since the PIT1 antibody 
recognizes all the isoforms, the results are not isoform-specific. Results of EMSA with 
whole cell extracts of LMH cells transfected with individual PIT1 isoforms showed 
robust binding of PIT1α, PIT1β1 and PIT1β2 to the proximal PIT1 binding site contained 
within an infra-red labeled probe. This binding was specific, as no binding was detected 
with a scrambled probe, and the specific binding was competed off with 100-fold molar 
excess of unlabeled probe. Surprisingly, PIT1γ exhibited significantly reduced binding 
even when the level of protein expression was comparable among the isoforms. This 
result was contrary to our hypothesis, which was based on the fact that DNA-binding is 
mediated by the POU-homeodomain which is perfectly conserved among all the 
isoforms. Thus, it appears that the reduced activation of the cGh promoter by PIT1γ is 
due, at least in part,  to reduced binding of the same to the proximal PIT1 binding site.   
 
Since multiple PIT1 isoforms (PIT1α, PIT1β1 and PIT1β2) activated the cGh promoter 
but to different levels (PIT1β1>PIT1α/Pit-β2>PIT1γ), we wanted to see if any isoform 
had a regulatory effect on another. Very few studies have looked at the effects of the 
presence of one isoform on the other(s) in regulating target genes (Sporici et al., 2005), a 
108 
 
condition that is encountered in the PIT1 expressing cells of the anterior pituitary. 
Specifically, we were interested in a possible negative regulatory role of PIT1γ on one of 
the activating isoforms. In a previous report, Bastos et al. (2006) have shown that ovine 
PIT1γ and PIT1δ, which showed no activation of the rat Prl promoter in HeLa cells, 
functioned as dominant negative repressors of PIT1 (wild type) when expressed together. 
To this end, we co-expressed PIT1β1 and PIT1γ in LMH cells to investigate a possible 
effect on cGh promoter activity. According to our results, co-transfection of PIT1γ did 
not have an effect on the transactivation potential of PIT1β1. The two other activating 
isoforms, PIT1α and Pit-β2, were also co-expressed individually with Pit-β1 to see if the 
combination leads to a synergistic activation of the cGh promoter. As seen from our 
results, co-expressing either PIT1α or PIT1β2 with PIT1β1 led to stimulation of the cGh 
promoter to a level significantly higher than that achieved with either isoform transfected 
alone. In these experiments, the doses were chosen such that they activated the cGh 
promoter and at the same time led to comparable levels of protein expression. For the 
combination PIT1α with PIT1β1, there is a possibly synergistic activation of the Gh 
promoter, while for PIT1β1 and PIT1β2, the combined effect is likely additive. Our 
results are the first to demonstrate such effects of co-transfection of PIT1 isoforms in 
chicken for any PIT1 regulated gene. 
 
Since PIT1 is known to bind DNA as a dimer (Holloway et al., 1995; Jacobson et al., 
1997), we wanted to test if the additive or synergistic effects shown by isoform co-
transfection are results of physical protein-protein interactions between the isoforms. We 
employed co-immunoprecipitation to detect PIT1β1/PIT1β2 and PIT1β1/PIT1α 
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heterodimerization. Co-immunoprecipitations in our conditions failed to capture any such 
physical interaction between the isoforms. However, in the absence of a positive control 
for known protein-protein interactions, we are reluctant to conclude that the isoforms do 
not form a heterodimer. It is entirely possible that the interaction may not be strong 
enough to withstand the physical stress of cell lysis and subsequent immunoprecipitation. 
Other reports of heterodimerization (Sporici et al., 2005) have employed bacterially 
expressed PIT1 protein with GST tags. In these experiments, in vitro translated PIT1 
proteins were purified and incubated with their dimerization partners that were obtained 
in a similar manner. These conditions provide highly enriched proteins and are not 
physiologically similar to conditions in vivo.  
 
Involvement of cAMP in GH synthesis has been shown in several species (Copp and 
Samuels, 1989; Tansey et al. 1993; Shepard et al. 1994, Argenton et al. 1996, Wong et 
al. 1996), and for promoters lacking a core CRE motif, the cAMP effect is thought to be 
mediated by PIT1 through phosphorylation and recruitment of CBP to the transcription 
complex (Xu et al., 1998, Zanger et al., 1999; Cohen et al., 1999). As seen from our 
results, PIT1β1 resulted in significantly higher activation as compared to PIT1α and 
PIT1β2. We hypothesized that enhanced interaction of PIT1 with CBP, resulting in faster 
recruitment of the same to the transcription initiation complex, is the mechanism 
responsible for the effect. To test this, we transfected c-myc-tagged C-terminal 773 aa of 
cCBP (cCBP773) along with PIT1β1 into LMH cells, but once again we failed to detect 
protein-protein interaction between PIT1 and cCBP by co-immunoprecipitation. Thus, 




The phosphorylation status of PIT1 response to CORT in e11 chicken pituitary cells was 
investigated using an anti-P-threonine antibody. PIT1 is a target of phosphorylation by 
PKA and PKC pathways in mammals. Previous (Bossis and Porter, 2003) and 
unpublished results from our lab have shown that GC induction of chicken somatotroph 
differentiation and Gh gene expression requires the involvement of p38 MAPK and 
MEK1/2 pathways (Malkiewicz, 2003; Ellestad, 2010). PIT1 is known to be 
phosphorylated at a conserved Thr residue located in the POU-domain that is conserved 
across isoforms. Also, CORT induces increased binding of PIT1 to the proximal Pit-
binding site of the cGh promoter (Narayana and Porter, unpublished), which can be a 
result of phosphorylation-induced conformational change. However, the requirement of 
phosphorylation seems to vary according to the gene being regulated and the species 
being tested. No report of PIT1 phosphorylation exists for any avian species. 
Unfortunately, we were not able to consistently detect phosphorylation of endogenous 
PIT1 from e11 chicken pituitary cells, either under basal or CORT-stimulated conditions. 
 
 
This project began with the hypothesis that the PIT1 isoforms will differ in their ability to 
activate the cGh promoter, and that this difference will be due to structural variations in 
the N-terminal transactivation domain. The first part of the hypothesis was supported, as 
three isoforms exhibited significant activation of the promoter, while PIT1γ showed 
minimal activation, if any. Even though we initially thought the isoforms will not differ 
in their ability to bind to the cGh promoter proximal PIT1 binding site, we were proven 
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wrong. PIT1γ showed no binding to this site, thus providing a possible explanation as to 
why it may not function as the other isoforms. Co-expression of PIT1γ did not lead to 
suppression of activation by PIT1β1, while co-expression of either PIT1α or PIT1β2 with 
PIT1β1 led to increased activation of the cGh promoter. The mechanism leading to this 
increased activation is not known. In conclusion, in this study we have identified a novel 
isoform of chicken PIT1 (PIT1β2) and have provided a comparative account of the 
transactivational properties of chicken PIT1 isoforms to regulate the cGh promoter. We 
have also postulated a possible mechanism behind the difference noted, and speculated 
on the purpose of having multiple isoforms of the same protein in the same cell type 















Chapter 3: Conclusion and future directions 
Conclusion 
PIT1 is a POU-homeodomain transcription factor essential for pituitary-specific growth 
hormone (Gh) gene expression. Several PIT1 isoform mRNAs exist in chickens which 
have not been characterized. The main aim of this study was to determine which, if any, 
of the chicken PIT1 isoforms regulated the Gh promoter. Our study is the first to report a 
comparative functional characterization of all known PIT1 isoforms in an avian species. 
We showed that three of the isoforms, PIT1α, PIT1β1 and PIT1β2 regulated the cGh 
promoter, while PIT1γ did not. Results from gel-shift assays show that PIT1γ did not 
bind the proximal PIT1-binding site of the cGh promoter as well as the other isoforms, 
suggesting a possible mechanism behind the inactivity. Our results, did not suggest a 
negative regulatory role for this isoform. In contrast, there seemed to be a functional 
advantage for having multiple isoforms expressed simultaneously. PIT1β1, the isoform 
that activated the promoter to the greatest extent, when co-transfected with another 
activating isoform (PIT1α or PIT1β2) brought about a significantly higher level of 
activation than any isoform alone. Whether this increased activation required or was 
facilitated by heterodimerization of two isoforms is not known.  However, identification 
of isoforms with specific functions will facilitate identification of their interacting 






Our study aimed to determine the ability of the chicken PIT1 isoforms to regulate the 
cGh promoter. Since chicken pituitary cells express all known isoforms, and possibly 
unknown ones, it was essential to perform the experiments in a non-pituitary cell line. 
After performing trial experiments in mammalian and chicken cell lines, LMH cells (a 
chicken liver carcinoma cell line) were deemed to be suitable for our purposes. However, 
this is not the native environment of PIT1. Hence, even though we obtained specific 
activation of the Gh promoter using our reporter construct, our findings need to be 
confirmed in pituitary cells. We have weighed in on the option of using a rat pituitary cell 
line. However, previous work from our laboratory has shown that the cGh promoter can 
be activated in the rat pituitary GH4C1 cell line in absence of transfected chicken PIT1 
expression construct. Moreover, our trial experiments have shown significant 
downregulation of PIT1β1 protein expression from transfected plasmid in GH4C1 cells. 
Pituitary cells, in both mammals and birds, normally have about 10-fold less abundance 
of PIT1β mRNA and protein (Morris et al., 1991; Kurima et al., 1999; Van As et al., 
2000), and it seems that such comparative levels are regulated in a pituitary-specific 
manner.  
 
Testing the effect of individual isoforms in cells of pituitary lineage will involve selective 
knockout of the others. Given the fact that the isoforms are encoded from a single gene, 
knockout of the entire gene is not a possible solution. Short hairpin RNA (shRNA)-
mediated gene silencing appears to be the most attractive way to achieve this. However, 
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there are two main impediments that could make achieving this goal difficult. Normally, 
multiple shRNAs are tested, and often used simultaneously, to obtain substantial 
silencing of a gene. Since the differences between the isoforms encompass relatively 
short regions and all are located toward the 5’end, designing sufficiently unique shRNAs 
will prove to be a challenge. Furthermore, shRNAs against multiple isoforms will need to 
be delivered into chicken pituitary cells, which have very low (5-10%) transfection 
efficiency. No chicken pituitary cell line exists. A way around this problem might be the 
use of adenoviral constructs encoding the short RNAs or some other mechanism of direct 
delivery of the shRNA into pituitary cells in culture. 
 
Binding of endogenous PIT1 to the endogenous Gh promoter in chickens under both 
basal and CORT-stimulated conditions has been demonstrated by our laboratory 
(Narayana, 2010). However, isoform-specific binding has been demonstrated by us only 
with PIT1 isoforms over-expressed in a heterologous system. Isoform-specific 
monoclonal antibodies will be required to demonstrate endogenous PIT1 binding, and 
producing such antibodies, while not impossible, will be difficult, as they would need to 
be designed against minimal N-terminal differences among the isoforms, reducing the 
number of unique sequences that can serve as epitopes.  
 
Since the main area of research by our group is regulation of Gh, we have not tested the 
ability of the isoforms to regulate other PIT1 regulated genes, such as prolactin, thyroid-
stimulating hormone β-subunit, or growth hormone-releasing hormone receptor. Testing 
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activational abilities of PIT1 isoforms for these promoters will provide an estimate of the 
specificity of isoform function.  
 
It will also be of interest to know which isoform mRNA and proteins are expressed in 
which cells of the PIT1 lineage. Co-localization experiments using antibodies against 
hormones unique to cell types would have been a simple approach but for the fact that 
isoform-specific antibodies are not available. We are currently working on determining 
cell-type specific isoform mRNA expression. The approach involves FACS sorting of 
pituitary cells based on fluorescence emitted by antibodies directed against pituitary 
hormones to obtain homogeneous populations of pituitary cell types. RNA extracted from 
these populations will be reverse transcribed, and the presence of PIT1 isoform cDNAs 
will be determined using quantitative real-time PCR.  However, experiments 
demonstrating the presence of mRNA should always be supplemented by those showing 
protein expression.  
 
Our results have shown an additive or possibly synergistic effect of co-transfection of 
two isoforms. Since PIT1 is known to bind DNA as a dimer, we tested if two activating 
isoforms bound as a dimer. Also, while investigating a possible mechanism underlying 
high activation by PIT1β1 compared to others, we tried to determine if PIT1β1 showed 
increased and tighter interaction with CREB-binding protein (CBP). However, we could 
not detect any interaction between the isoforms or between PIT1 and CBP by co-
immunoprecipitation. Previous reports of dimerization of PIT1 have all employed 
purified in vitro translated proteins, conditions that do not represent the actual cellular 
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environment (Ingraham et al., 1990; Holloway et al., 1995; Sporici et al., 2005). Reports 
of interactions of PIT1 with other transcription factors or transcriptional activators, with 
one exception of PIT1 interaction with GATA2 (Gordon et al., 1997), have all employed 
in vitro translated purified protein as well (Voss et al., 1991; Verrijzer et al., 1992; Nalda 
et al., 1997) . We do not know if the isoforms do not dimerize, or if the interaction is 
dynamic, and therefore, transient. It will be a sensible approach to first test dimerization 
in vitro by other methods such as FRET or surface plasmon resonance, and then use a 
functional assay such as a two-hybrid system to detect interactions in vivo. 
 
In conclusion, while our work made a significant contribution in elucidating the fine 
details of regulation of Gh by chicken PIT1 isoforms, much remains to be known about 
the process. Future advancements in technology will hopefully aid in circumventing the 
problems that are faced currently and help elucidate the mechanism of regulation of Gh 
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